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RÉSUMÉ 
Le virus respiratoire syncytial humain (VRS), un pneumovirus, est URe cause importante 
de maladie des voies respiratoires inférieures. L'infection au VRS pendant la petite 
enfance est associée au développement de la bronchiolite et de l'asthme. Il n'existe aucun 
médicament ou vaccin. qui prévienne l'infection à VRS. La seule thérapie antivirale 
disponible estla ribavirine, réservée. aux personnes à haut risque de maladie grave. Des 
études récentes ont démontré que des 'smaU interfering RNAs' (siRNAs) dirigés contre 
les ,protéines virales P et NSI inhibaient la réplication le VRS. Par ailleurs, on a aussi '. 
cherché à prolonger l'activité des siRNAs en leur apportant des modifications chimiques. 
Une de ces modifications est le F-ANA (acide 2'deoxy-2'-tluoro-f3-D-arabinonucléique). 
Le présent travail étudie l'efficacité des siRNAs modifiés au F-ANA à inhiber la 
. réplication dU VRS. In vitro, les siRNAs F-ANA ciblant les protéines viralesP .et NS 1 
inhibent plus efficacement la réplication virale. In vivo, à plus forte concentration, les 
siRNAs modifiés. ou non au F-ANA et la ribavirine inhibent la synthèse des protéines, 
virales avec une efficacité comparable (inhibition de 44% ± 6 pour le siRNA non-
modifié, 47% ± 8 pour le siRNAF-ANA et 41% ± 9 pour la ribavirine). Cependant, à 
tàible dose, l'efficacité du siRNA F-ANA est 84% supérieure à celle du si RNA non-
modifié, un taux qui surpasse l'efficacité de la ribavirine de 57%. Les modifications F-
ANA ont donc le potentiel d'améliorer les performances des siRNAs en tant qu'agent 
prophylactiques ou thérapeutiques conn:e le VRS. 
Mots clés : Virus respiratoire syncytial, agents antiviraux, ARN d'interférence, smaU 
interfering RNA, modifications avec :.:'-ANA, phosphoprotéines virales, protéines non 
structurale virales, ribavirine, modèle de souris. 
IV 
ABSTRACT 
Human respiratory syncytial,virus (hRSV), a pneumovirus, is the major cause of severe 
lower respira tory tract disease in young children, the elderly and the immunosuppressed~ 
Additionally, hRSV infection during infancy has been associated with the development of 
bronchiolitis andasthma. Despite extensive research, no reliable drug or vaccine 
currently exists that can prevent RSV infection. The only antiviral therapy available is 
ribavirin, whose use is reserved for persons at high risk for severe disease. Recent studies 
have shown that smàll interfering RNAs (siRNAs), targeting viral P prote in and also viral 
NSI protein inhibited RSV growth in culture and in vivo. Recently, efforts have been 
made to enhance stability and duration of ~ctivity of siRNAs through chemical 
,modifications. One such modificationis F-ANA (2'deoxy-2'-fluoro-~-D;.arabinonucleic 
acid). The efficacy of siRNAs modified with F-ANA at inhibiting hRSV replication was 
investigated both in vitro and in vivo: In vitro screening demonstrated greaterefficacy of 
siRNA targeting viral P protein than NS 1 protein. In vivo, both unmodified and F-ANA 
modified siRNAs targeting viral P gene inhibited hRSV protein levels equally weil at 
high doses (44% ± 6 for unmodified siRNA and 47% ± 7 for F-ANA modified siRNA), 
comparable to 41 % ± 8 inhibition achieved by ribavirin. At lower doses, the F-ANA: 
modified siRNA demonstrated 84% increase in efficacy to inhibit hRSV replication 
compared to unmodified sequence, exceeding ribavirin by 57%. In summary, F-ANA 
modifications have the potential to optimize siRNAs as prophylactic and/or therapeutic 
agents against hRSV infection. 
Key words: Respiratory syncytial VIruS, antiviral agents, RNA interference small 
interfering RNA, F-ANA modifications, viral phosphoroproteins, viral' nonstructural 
proteins, ribavirin, mou se modd. 
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GENERAL INTRODUCTION 
2 
Ruman Respiratory Syncytial ViruS (hRSV), an RNA ViruS of the Paramyxoviridae 
family, is recognized as the most frequent cause of severe lower respiratory tract disease 
in infants and young children worldwide 1. hRSV infects approximately 50% of infants 
. during the first year of life and almost all children by age of two. Lower respiratory tract 
infections, such as bronchiolitis and pneumonia, result in an ·estimated 51,000-82,000 
hospitalizations annually among young children in the United States 2. Bronchiolitis is 
associated with long-term impairment of pulmonary function and often 
hyperresponsiveness of the airways after an RSV-infection during infancy'may presage 
the development of asthma later on in children and adults 3. 
Acquired immunity provides neither an efficient protectionagainst re-infections nor 
reduction in viral shedding after infection, thus acquired immunity is incomplete and not 
durable. Despite extensive research, no reliable drug or vaccine currently exists that can 
prevent RSV infection. Two forms of anti-RSV antibody prophylaxis are available on the 
market, RSV-IGIV and palivizumab, both of which are questionable in their cost-
effectiveness 4, 5, 6. Currently treatment is supportive and the sole antiviral therapy 
available is Ribavirin, whose use is reserved for persons at high risk for severe disease, 
and still remains controversial in efficacy and expensive 6. In addition, due to its very .. 
labor-intensive administration methocis and its potential hazardous effects on the 
caregivers 7, its use has been questioned on economic and safety grounds. 
Recent studies have shown that small interfering RNA duplexes (siRNAs) targeting 
either the viral P prote in 8, an essential subunit of the RSV replication machinery, or the 
viral NS 1 prote in 9, another essential component of viral repli cation, strongly inhibited all 
RSVgrowth in culture and also in vivo, when administered intta-nasally. The problem 
remains of enhancing siRNA stability so that it can find its way into cel1s. Intetestingly, 
an increase in activity and an enhancement of seruin stability of siRNAs has been 
observed when modified with F-ANA (2'deoxy-2' -fluoro-~-D-arabinonuc1eic acid) at 
specific regions of the sens~ or antisense strands in culture 10, 11, however has nbt been 
fully examined in an animal model. The efficacy of siRNA modified with F-ANA to 
3 
inhibit hRSV replicaiion in vitro and also in vivo in a murine model of RSV infection was 
. therefore investigated. 
f." r 
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CHAPTERII 
RESPIRA TORY SYNCYTIAL VIRUS 
ANDDISEASE 
>'.1 .. ' : • ",J\. ., .. 
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5 
2.1 HISTORY 
In 1956, a group of young chimpanzees in a colony outside Washington, De (USA) were 
demonstrating respiratory symptoms of a cold-like illness 12. Morris, Blount and Savage 
recovered the cytopathic agent from one of these chimpanzees, with an upper respiratory 
tract illness, wlÎich induced symptoms of coryza, runny nose, and malaise. They named 
, . 
this agent "chimpanzeecoryza agent", which was responsible fot an outbreak of severe 
coryza illness in adolescent monkeys in the previous year 12, 13. Upon examination of the 
entire colony nearly all of the chimpanzees were found to be infected. Ruman contacts 
working with the chimpanzees were also shown to be infected and had exhibited mild 
upper respiratory tract illness and coryza, however at levels less severe than observed in 
the chimpanzees; Subsequent studies identified two major isolates of the virus recovered 
from other patients with upper respiratory tract illnesses 12. In 1957, the initial name of 
"chimpanzee coryza agent" was changed to respiratory syncytial virus (RSV) because of 
its selectivity for the respiratory tract and the characteristic tendency of infected cells to 
fuse together and form giant cell syncytia in tissue culture 13, 14. 
2.2 EPIDEMIOLOGY 
Severe respiratory infection in infants and young children was first recognized over 150 
years ago and termed "congestive catarrhal fever." Based on clinical descriptions 
published at the time, there is a high probability that the disease described can be 
attributed to RSV 15._ Following the discovery and identification of RSV in the late 1950s 
and early 1960s, epidemiological studies clearly established it as the most important 
cause of serious respiratory tract infection in infants and young children 16, 17, 
Approximately 25 years later, RSV is recognized as the leading cause of infection of the 
lower respiratory tract in infants and young children 1. It is the single most important 
cause Of hospitalization during the first year of life 18, infecting around 50% of Infants 
during the first year oflife and almost all children by the age of two 19. It is the leading , 
cause of death due to viral illness in children younger than 1 year with a mortality rate in 
6 
this age group 10 times gteater than that from influenza 20. Unlike the common cold or 
flu, RSV continues to be the leading kiUer among infectious diseases with an annual 
'death toU of about one mÜlion worldwide 21, 22. Although RSV infection was reported in 
1 
adults with pneumonia in the 1960s, it has only been during the past two decades that the 
potential for widespread occurrence with serious clinical impact in this population has 
been recognized 23, 24, 25, 26. RSV has a global distribution and it is a seasonal infection, 
with peaks around winter and/or spring 27. 
Two major antigenic subgroups of respiratory syncytial virus (designated A and B) have 
been described, differentiated mostly on the basis of reactivity patterns between 
monoclonal antibodies and the viral glycoprotein (0' protein) 28, 29. Both subgroups are 
infectious: one strain tends to dominate during an individual epidemic in an individual 
location, although at times both strains can be isolated from patients in the same area 30. 
In addition, a number of studies suggest that Strain Amay result in more virulent 
infections than Strain B 31, however there is great vaiiability, possibly due to viral burden 
and individual host factors. Along with these 2 strains, several subtypes of each strain 
have been identified 32, 30. In the United States and United Kingdom, ,Strain A i~ found 
more commonly, although it has been observed to alternate with Strain B in a somewhat 
. 1 fi 33 S . B h lrregu ar pattern rom year to year . tram , owever, appears more common1y in 
epidemics in Europe 34. 
2.3 VIRAL STRUCTURE, REPLICATION AN~ INFECTION 
2.3.1 Virion structure 
Respiratory syncytial viruses, both bovine (bRSV) and human (hRSV), are enveloped 
RNA viruses and members of the Pneumovirus subfamily, of the family Paramyxoviridae 
35. The Paramyxoviridae family includes two genera, Morbillivirus (measles virus) and 
the paramyxoviruses (containing, e.g., parainfluenza virus, types l, 2, and 3, and mumps 
virus) 32. The RSV virion is about 150-300 nm in diameter consisting of a nucleocapsid 
7 
core that is packaged within a lipid envelope 36 (Figure 1). Each of the viral mRNAs 
encodes a major viral protein 37. 
F protein 
SH protein 
.--- G protein 
Negative ssRNA 
M (matrix) prote in 
N, P, L proteins 
Figure 1. Respiratory syncytial virus structure. The RSV virion is about 200 nm in size and consists of 
a nuc1eocapsid within a lipid bilayer. The major nuc1eocapsid protein N, the phosphoprotein P, the large 
polymerase subunit L, the anti-termination factor M2 and a single-stranded RNA genome of negative 
polarity compose the RNP complex. The attachment protein G, the fusion protein F and the sm ail 
hydrophobie protein SH are the three transmembrane surface glycoproteins present on the viral surface. 
The matrix protein M forms a scaffold on the inner layer of the envelope. Figure modified from (Hacking, 
2002) 37. 
The symmetrically helical nucleocapsid (RNP complex) is 12-15 nm in Slze and is 
composed of the nucleocapsid protein N, the phosphoprotein P, the large polymerase 
subunit L and the M2-1 protein. The envelope is a lipid bilayer derived from the ho st 
plasma membrane and containing on its surface virally encoded transmembrane 
glycoproteins (G) responsible for attachment, the fusion protein (F) and the small 
hydrophobie (SH) protein, whose function is unknown however speculated to also be 
involved in cell fusion 38. Inside the lipid bilayer is a scaffold formed by the matrix 
protein (M), which connects the viral membrane with the RNP complex 30, 32 (Figure 1). 
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2.3.2 Genome organization 
The RSV genome is a 15,200 nucleotide-long non-segmented single-stranded negative-
sense RNA containing 10 genes that are transcribed into Il major sub-genomic mRNAs 
39,40,41,42 (Figure 2), AlI mRNAs are capped at the 5'-end and polyadenylated at the 3'-
end by the viral polymerase, however genomic and anti-genomic RNA are neither capped 
nor polyadenylated and are components of the nucleocapsids. Transcription and 
replication is initiated from the 3' -end in an obligatory sequential manner with only a 
fraction of the virally encoded RNA-dependent RNA polymerase (RdRP), minimally 
composed of the large protein (L) and the phosphoprotein (P), moving to the next gene. 
This mechanism creates a gradient of transcription al attenuation with distance from the 
transcriptional start-site indicating the required relative abundance of the encoded 
proteins (Figure 2). The overall strategy of RSV gene expression is common to aIl 
members of the negative-strand RNA virus super-family 43, 44. The initial rounds of 
transcription, known as "primary" transcription, are carried out by the RdRP activity 
associated with the incoming viral genome. The transcribed mRNAs are translated into 
de nova viral proteins including more RdRP, which boosts new rounds of viral gene 
expression. 
3' NS1 NS2 N P M SH G F Ml L 5' 
t , 4;f (lSSj ....,... ........ ..., 
S1t of" 1191 "6 ,JI oIOS 91' 'm 
1.19 I~ .191 }of' 1}6 60f lSI8 S'of 
'''' 
1165 
Figure 2. RSV genes and the sizes of their rnRNA and encoded proteins. The RSV genome is a single 
stranded negative sense RNA of a 15,200 nuc1eotides that is transcribed into II major sub-genomic 
mRNAs. Transcription is initiated from the 3'-end with only a fraction of the polymerase moving on to the 
next gene. This mechanism creates a gradient of transcription al attenuation with distance from the 
transcriptional start-site indicating the required relative abundance of the encoded proteins Figure modified 
from (Hacking, 2002) 37. 
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2.3.3 Viral proteins 
Nine of the 11 major proteins, N, P, M, SH, G, F, M2, and L, are structural proteins 
(present in infected cells and virions) and surface glycoproteins 30, 32 (Figure 2). Three of 
nine structural proteins are transmembrane surface glycoproteins~ (G, F, and SH), of 11-
20nm in size, embedded in the lipid bilayer derived from the host cell membrane, at, 
intervals of 6-10 nm 37. The viral nuc1eocapsid core is a symmetrical helix with a helical 
diameter of 12-15 nm 37,38 and composed of N, P, L proteins (which together comprise 
the viral replicase) and M2 open reading frame 1 (M2 ORF-l) (Table 1). FinalIy, two 
proteins (NS 1 and NS2) are non structural viral products that accumulate in infected cells 
but are present in only scarce amounts in mature virions 39, 45. 
Genome 
3' 
NS1 
NS2 
N 
P 
M 
SH 
G 
F 
M2 
L 
5' 
Proteins 
NS1 
NS2 
N 
P 
M 
SH 
G 
F 
M2-1 
Î 
M2-2 
L 
Functions 
Non-structural protein: Unknown function (Essential in replication?) 
Non-structural protein: Unknown function (Anti-IFN a and J3 activity?) 
Nucleocapsid protein: structural protein essential for transcriptional activity 
Phosphoprotein protein: essential structural protein and cofactor of the polymerase 
Matrix protein: viral assembly 
Small hydrophobie protein: function unknown; not required for replication nor 
syncytium formation 
Transmembrane protein: mediates viral attachment; membrane bound and 
secreted forms; neutralizing antigen 
Fusion glycoprotein: mediates syncytial formation, penetration, neutralization and 
protection 
M2-1 protein (upstream ORF): transcription and elongation factor 
M2-2 protein (downstream ORF): regulation of transcription and RNA replication 
Major polymerase subunit 
Table I. The RSV genome, encoded viral proteins and functions. The RSV genome is a single stranded 
negative sense RNA of a 15,200 nucleotides that is transcribed into II major sub-genomic mRNAs. Each 
viral protein encodedby the genes play a key function in the repli cation and transcription of the virus. Nine 
are structural proteins and the remaining two are non-structural proteins. ' 
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The RSV F protein is a transmembrane glycoprotein essential in the role of viral entry, by 
,mediating surface fusion of the virion envelopewith the host's cellular plasma membrane 
and also in the formation of syncytium, late in the infectio~. The F protein (70 kDa) Is a 
type l transmembrane glycoprotein with a cleaved N-terminal signal sequence and a 
transmembrane anchor near the C terminus, and is similar to that of the, other 
Paramyxoviruses iti structure and function 41, 46, 47, 48. The F protein is synthesized as a 
precursor F 0 that is activated by cellular protease( s) and cleaved into two subunits, FI and 
F2, linked by disulfide bonds, after the synthesis and modification by the addition of N-
linked sugars 49. The fusion protein is protein that induces in the human host the most 
important responses,. including humoral and cytotoxic T -lymphocyte responses 50. 
The RSV G prote in is a heavily N- and O-glycosylated and large type II transmembrane 
glycoprotein, involved in mediating viral attachment but not essential for propagation 51. 
The G protein (90 kDa) has a number of unusual structural features, including a large 
number of proline, setine andthreonine residues and a significant content of O-linked 
oligosaccharides 52, 53 and it also as the lacks neuraminidase and hemagglutinin 36. Both 
glycoproteins have been shown to be major antigenic determinants of the virus 36 
especially the G prote in, dividing the virus into the two major subgroups, A and B, as 
described above 54. 
The small hydrophobie SR prote in (7.5-30 kDa) isa short Integral transmembrane protein 
and is present in glycosylated and non-glycosylated species in the form of oligomers. Its 
function is still unkllown, however it has been established that it is not required for viral 
replication or syncytium fonnation in vitro 37, whereas attenuation has been achieved by 
targeting the SR protein in the lower respiratory tract in vivo 55. 
The matrix prote in M is a non-glycosylated protein that forms a scaffold on the inner side 
of the viral enve1ope. It plays an important role in virus assembly and, budding by 
mediating the association between RNP complex and cell plasma membrane 56, 57. In 
early infection, M prote in localizes the nucleoprotein into the nucleus where it possibly 
inhibits host-cell transcription, and also inactivates transcription activity of the RNP 
Il 
before packaging 57. RSV M protein has also exhibited sorne RNA-binding capacity 
however the actual function of this interaction still remains unc1ear. 
The N (44 ~a), P (34 kDa), and L (~200 kDa) proteins, co-purified with the 
nuc1eocapsid, are all. essential for RNA replication and transcription 37. The major 
nuc1eocapsid protein is the nuc1eoprotein. It binds to genomic and antigenomic RNA 
, . 
conferring RNase resistance to the nuc1eocapsids.' The exact positioning of the RNA 
relative to the N molecules is not yet determined 5~. It has also been suggested that the N 
protein itselfmight ~:e a comportent of the promoter 59. The phosphoprotein P is the major 
phosphorylated species, in which it acts as a chaperone for N protein and is essential 
tùgether with N protein for encapsidation. The phosphoprotein P is also a polymerase 
cofactor which functions by converting initiated polymerase into st~ble complex and its 
phosphorylation of itself is imperative for its function 60. Bitko et al. have derilonstrated 
the importance of P protein in viral repli cation and propagation, through achieving 
attenuation of viral repli cation by inhibiting the viral P mRNA 8. The large protein L is 
the major RNA-depe?dent RNA polymerase subunit and it is bound to its cofactors, the 
phosphoprotein P and M2-l by the Nprotein 61. The L protein together with the p'protein 
fomis the L-P complex and is proposed to be responsible for the recognition of the 
promoter, RNA synthesis, capping and methylation of the 5' termini of the mRNAs and 
polyadenylation of their 3' ends. Evidence has shown that the L protein contains the 
enzymic domains required for these processes and its multifunctional nature tallies with 
its size, with t~e L gene accounting for almost half of the RSV coding potential 62. 
M2 ORF-l and M2 ORF-2 are two open reading frame products of·the M2 (22 ~a) 
protein that are important in the production of full-Iength mRNA by polymerase and in 
the regulation of transcription 41. The M2-l protein is a transcription elongation factor 
whichcomplexes with N, P, and L to ensure efficient production offull-Iength mRNA 37. 
The M2-l protein is encoded by the upstream translational ORF of the M2mRNA, 
whereas· the M2-::2 is a second, distinct prbtein also transcribed from the M2 gene, with 
defined properties in transcriptional regulation. The M2-2 protein overlaps with the first 
and encodes a putative negative regulatory activity on viral transcription and thus appears 
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to be an Il th RSV gene. The SR, M, and M2 proteins are all envelope-associated proteins 
36 
The two non-structural proteins (~14-l5 kDa), NS 1 and NS2 proteins, are encoded by the 
first two genes in the viral genome and it is this presence that is perhaps what 
distinguishes the Pneumo virus genus from the rest of the Paramyxoviridae family. The 
proteins are so named because they are not packaged into the mature virion. N onetheless, 
both genes are expressed in the infected cell and the mRNAs are rel,atively abundant due 
to the promoter-proximal (3' end of thenegative-stranded genome) location ofthe genes 
63. The NSI and NS2 proteins each containthe same found carboxy-terminal amino acids 
but otherwise are unrelated. While the function of both nonstructural proteins is still 
unknown, research has shown an anti-interferon a and B activity of these proteins 37,64. 
The NS 1 protein has been suggested to be a potent inhibitor of intracellular RSV 
transcription and RNA replication 9, 65, while the NS2 protein decreased Stati levels in 
airway epithelial cells, and thus may lliodulate type 1 interferon signaling and gene 
expression 66. Furthermore, the deletion of ei~her NS 1 or NS2 severely attenuated RSV 
infection both in vivo and in vitro, suggesting that the NS proteins play a vital role in viral 
replication 55, 67, 68, 69. 
2.3.4 Viral replicative cycle 
The viral cycle of RSV begins with the attachment and entry into the host ce li , 
predominantly airway epithelial cells~ which line the noseas well as the large and small 
airways. Binding and entry of RSV into these target cells is mediated by the interaction 
between the G and the F proteins, with the host cell (Figure 3). The specifie cellular 
receptor(s) for the G protein has not yet been identifièd however cell surface 
glycosaminoglycans, such as heparin sulfate and chrondroitin sulfate B, have been shown 
to have an important function in in vitro infection through a putativeheparin binding 
domain in the G protein 70. Interestingly, recombinant RSV virus es with either mutated G 
protein or simply lacking the G prote in are still infectious in cell cultures, whereas 
attenuation of infectivity is demonstrated in vivo 71, 72. This observation suggests that the 
13 
G protein is non-essential for cell attachment but has other functions that may influence 
the efficiency of the process, as it con tains a motif at 182-186 amino acids common to the 
CX3C chemokine fractalkine 53. lt has been shown that the G prote in binds to the CX3C 
receptor (CX3CR1) and can facilitate RSV infection 73. 
The F protein is absolutely required by RSV and can mediate attachment on its own. The 
fusion of the viral envelope or infected cell membranes with uninfected cell membranes 
and the fonnation of syncytium is an essential step in the virus life cycle 74 . Viral uptake 
appears to occur by fusion rather than endocytosis. Once incorporated into the target cell 
membrane, the nucleocapsid (RNP) is released into the cytoplasm, where the genome is 
transcribed and replicated (Figure 3). 
Viral fusion and nucleocapsid release 
--
genomlcRNA 
mRNA traneCriptlon2f 
in 'the cell cytopla8m n 
~ ~ ~ication 
888~ ~ :~o r1~8 
o ... Co-ordlnatad 
'II aaaembIy of virai proteine 
and virlll RNA 
Budding of mature virion 
RSV ceU ta celi 
fuaionand 
ayncytia 
formation 
Figure 3. The schematic representation of the replicative cycle of RSV. The attachment protein Gand 
fusion protein F mediate RSV entry and uptake respectively. After the viral enveJope has been incorporated 
with the ho st cell membrane, the nuc1eocapsids (RNPs) are released into the cytoplasm, where the en tire 
replication occurs. RNA transcription and replication is followed by encapsidation and budding on the cell 
surface ofnewly fonned virions. Figure modified from (Hacking, 2002) 37 . 
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The entire RSV replicative cycle takes place in the cytoplasm beginning with the 
transcription of the genome into ten monocistronic, 5' -capped, methylated and 3'-
polyadenylated mRNAs by the viral RNA-dependent polymerase complex 61 (Figure 3). 
RNA syrtthesis occurs in a sequential manner from the 3' -~nd of the genomewith the 
polymerase complex terminating and reinitiating mRNA transcription at each junction. 
, ' 
Re-initiating can be occasionally inefficient and this results in a gradient of mRNA 
decrea~ing proportionally to the distance of the gene from the 3' -end of the genome. 
The polymerase complex is also responsible for the synthesis of ahtigenomic RNA, 
resulting in a complementary positive-sense copy of the viral genome. The antigenomic 
RNA represents a replicativè intermediate that is less abundant in comparison to the 
genomic RNA. However, both RNAs are packed into virions in equal proportions. 
Antigenomic and genomic RNA synthesis correlates with protein translation suggesting a 
need for co-synthetic encapsidation. Where RSV differs from other Paramyxoviruses is in 
the switch between RSV transcription and RNA replication, as it seems to involve the 
( 
M2-2 protein and is not dependent on the intracellular levels ofN and P proteins 75. Thus 
the M2-2 gene oversees this transition from transcription to production of genomic RNA. 
r,?uring the earlier stages of infection, low leve1s of M2-2 corre1ates with a high 
transcriptional 'rate, whereas afterwards, when the intracellular levels of M2-2protein 
increase, transcription is inhibited in favor of replication 76. Replication involves 
generation of a complete, positive-sense RNA complement of ,the genome, the 
antigenome, which in tum acts as a template for genome synthesis. The genomes are then 
incorporated into nucleocapsids as they are synthesized and recycled through the RNA-
synthesis pathways, or are transported to the plasma membrane for assembly into virus 
particles (Figure 3): 
Assembly of the nucleocapsids is entirely intra-cytoplasmic. The N protein associates 
first with genomic and antigenomic RNA followed by P and L. Association of the 
nucleocapsids with the nascent envelope is mediated by the M protein, through a series of 
interactions by coordinating the assembly of the envelope proteins F and G, via their 
cytoplasmic domains, with the nucleocapsid proteins N P and M2-l 77. Once ass~mbled, 
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nucleocapsids are transported close to the ceU surface and bud at specific plasma 
membrane patches where glycoprotein G clusters. Budding appears to be the reverse of 
penetration and occurs in vitro on the apical ceU surface (Figure 3). 
, 
2.4 DISEASE AND CLINICAL RELEV ANCE 
2.4.1 RSV infection and transmission 
. The virus undergoes replication in the nasopharynx, and is then spread to the lungs via 
the respiratory epithelium or aspiration of secretions. Inoculation is via the upper 
respiratory tract and the virus is spread downwards to the lower respiratory tract along the 
. respiratory mucosa through syncytial formation and epithelial ceUsloughing 78. Lower 
respiratory infection follows 1-3 days later 79. There is however no systemic spread and 
the infection is confined to the respiratory mucosa 78. 
Respiratory syncytial virus is very contagious and' is thought to spread by large droplets 
of secretions (i.e. from sneezes) from an infected person. This oœurs via direct,contact 
with infectious secretions on envlronmental surfaces or through close contact with a 
person who has an active infection 80, 81, 82. An example of this close contact may be 
hand-to-eye or hand-to-rtasàl-epithelium following han~ contact with infectious 
secretions or even hand-to-hand transfer. However, studies have shown that no infection 
. oœurs if a person is at a distance of greater than six feet from an infected individual, thus 
the theory of small particle aerosol spread is rejected 83. The virus is highly resistant and 
can survive on surfaces long after it has been in contact with an infected persôn. Nasal 
secretions on tissue or cloth are infectious for up to 30 min, whereas those on hard 
surfaces such as countertops, stethoscopes or silverware are infectious for at least 6-12 
hours. After the initial contact, an incubation period of 2-8 days follows 15, in which, the 
infected person will conimonly exhibit mild to moderate nasal congestion and low-grade 
fever and a productive cough with mucous secretion. However, these sy~ptoms may 
persist as an upper respiratory infection for several weeks and then resolve without 
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further incident, particularly in patients who have had a previous RSV infection 30. 
Due to the extremely contagious nature of the virus, an infected person will remain 
contagious as long as the virus is being shed. Shedding of the virus begins within a day or 
so of infection, often before the onset of major signs of illness 81. Shedding of the virus is 
highly variable and appears to be roughly paralleled with the age of the person, the 
severity of the infection, and whether the infected person is immunocompromised. 
Infected adults would typically shed the virus for 3-7 days following infection 84. Since 
age seems to affect the shedding, infants would normally shed for up to 14 days in lighter 
infections, however ipfants less than 6 months of age with severe infections may shed for 
up to 3 to 4 weeks, thus increasing its contagious nature. OIder children and adults may 
only shed the virus for 3 or 4 days 80, 85. Immunocompromised individuals may shed for 
several months following an infection 86. 
2.4.2 Clinical symptoms 
RSV often causes an upper respiratory tract infection in infants and children. It is 
characterized by symptoms of rhinorrhea and cough. Lower respiratory tract infections 
are generally associated with expiratory wheezing (often referred to as bronchiolitisor 
wheezy bronchitis), pneumonia cart occur with RSV infection and bacterial acute otitis 
media can follow 30, 3,6. Also, approximately a third of RSV-infected children develop 
acute otitis media 87. Acute otitis media is characterized by the presence of fluid, typically 
pus, in the middle ear with symptoms ofpain, redness of the eardrum, and possible fever .. 
RSV is the causative agent in about 50% of infant pneumonia and 10:·-30% of pediatric 
bronchitis 88. 
The clinical profile of RSV infection differs according to age. In neonates, RSV 
infections differ from those in older children and apnoea (the cessation ofbreathing) may 
. be the onlysymptom· of infection. Almost aIl infants (6 weeks to 2 years of age) will be 
infecfed with RSV, the primary infection being often asymptomatic. However, RSV 
infection in infant· will involve the lqwer respiratory tract and cause bronchiolitis and 
pneumonia. Although this occurs in a minority of infants, it becomes the number one 
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cause of hospitalization in this age group. In oIder children, infections areusually less 
se~ere. The mortality in healthy children is extremely low, but in immunocompromised 
patients (including children infected with human immunodeficiency virus, children with 
combined immunodeficiency syndrome, children undergoing chemotherapy for leukemia, 
and children who have undergone transplantation), in patients with cardiac abnormalities 
and in cystic fibrosis patients, RSV infection is often life threatening 88, 89, 90, 91. In the 
elderly, RSV infection of the lower respiratory tract can manifest itself in the formof 
pneumol1ia 30, 36. In adults and the elderly, infection of the upper respiratory tract 
manifests commonly with symptoms such as rhinorrhea, nasal congestion, pharyngitis, 
and cough 30, 36. 
In addition, RSV infection may trigger acute respiratory distress syndrome with 
. . '- ) 
substantial morbidity and mortality 80. RSV infèctions leading to ARDS appear to have , 
long-term negative consequences similar to that of patients with other pulmonary 
diseases 30. Infected patients hospitalized for RSV lowef respiratory tract infection may 
develop recurrent wheezing during a l-year follow up. The occurrence of wheezing was . 
significantly higher in infants with airflow limitations than in those without airflow 
limitation during the acute infection 92, 93. Although the persistence of wheezing has been 
established 94, the relationship between RSV and subsequent asthma and atopy is not 
nearly as· clear 95. A number ~f studies appear to have found at· least a statistical 
connection between RSV infection and asthm~ in youngchÙdren 3,96,97,92,. 
2.5 THE IMMUNE RESPONSE TO RSV 
The immune response to RSV infection is similar tothat of any other infection, in thatit 
is comprised of an innate response, and subsequently by activation of humoral and cell-
mediated immunity. However, natural infection with RSV does not provide efficient 
protection against re-infections, indicating that the acquired immunity is incomplete and 
unstable. Ineffectiveness of the immune response against RSV infection has hindered the 
development of effective vaccines against both the bRSV and hRSV. The other' major 
1 
complication is that prior vaccination can actually enhance the severity of the disease 
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during subsequent natural infection 98, 99, 100, 101. Humoral immunity plays a key role in 
limiting the severity of subsequent infections, however does not offer a complete 
protection against RSV infection. 
2.5.1 The innate immune response to RSV 
Respiratory epithelial cells, are not only the principle target for RSV infection but are 
\ 
also the tirst line of defense in the innate immune response'to the virus, followed by the 
1 
involvement of antigen presenting ce Us, namely macrophages and dendritic ~ells. Not 
only do respiratory epithelial ceUs release nitricoxide (NO) upon infection and produce 
opsonins and coUectins (which are important in the clearance of the virus), but also 
sècrete a rànge of 'inflammatory mediators, su ch as chemokines, leukotrienes and 
cytokines 37,102,103,-104, such as intraceUular adhesion molecule (ICAM)~I 105, interleukin 
(IL)-8 106 and RANTES (Regulation upon activation normal T cell-expressed and 
secreted) 107. The release of such inflammatory mediators initiatesmaturation and 
chemotaxis of macrophages and induces neutrophils, eosinophils, and CD4+ T helper 
cells. In addition to the action of epithelial c'eUs, alveôlar macrophages are very important 
in the innate immune defense against R~V as they rnay regulate the immune response 108, 
and when infected release pro-inflammatory cytokines 109, such as tumor necrosis factor 
(TNF) alpha, IL-10, IL-6 and IL-8 which are involved in the regulation of inflammation. 
In both the macrophages and epithelial ceUs, RSV has been shown to induce the 
activation of nuclear factor kappa-B (NF-KB), which in turn stimulates transcription of 
genes affiliated with the antiviral response 110, Ill, NF-KB 'also plays a crucial role in the 
. early stages of innate immune response, mainly via the Toll-like receptor (TLR) signaling 
pathway 112, 1I3. TLRs are type 1 transmembrane pro teins and are evolutionary conserved. 
pattern recognition receptors, which respond to pathogen-associated molecùlar patterns. 
PAMPs include Iipopolysaccharides, nonmethylated CpG DNA and dsRNA 114, 115, 116. 
Cytokine and chemokine production in RSV-infected ceUs involve the Toll-like receptor-
. signaling pathway.' Recently, glycoprotein F of RSV was shown to activate. TLR4, 
possibly through their interaction with the surface molecule CD 14, expressed primarily 
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on resting monocytes/macrophages 117, 118 The role of several TLRs is still cUITently 
under extensive examination. 
2.5.2 Humorallantibody-mediated immunity to RSV 
During the first 2 months of the life of a newborn, protection against infection is 
passively acquired via maternaI immunoglobulins. Despite this fonn of "acquired" 
immunity, the presence of maternaI antibodies decreases gqldually during the first 6 
months of life, leaving most infants un-protected against RSV between 2 and 4 months of 
age 119. Thus the humoral response is stronger if primary infection with RSV occurs after 
6 months of age. These responses are also enhanced after each subsequent episode of re-
infection throughout life. However, not aIl humoral responses are favorable. For example 
RSV-specific IgE may also play a role in the increase of severity of the disease 120, 121, 122. 
McIntosh and colleagues detÀonstrated that secretory antibodies (IgA)were defective in 
neutralizing the virus in vitro, which may explain the failuTe of immunity during the early 
stages of an infant's life 123. Similarly, increased serum IgG titers do not entirely 
guarantee that a person will be protected from acquiring a new RSV infection or that a 
future disease will be mild. Thus. humoral immunity does not appear to pro vide a 
complete protection against RSV infection and CUITent evidence in the literature has 
focused on the importance of cell-mediated immune response in viral clearance. 
2.5.3 Cell-mediated immunity to RSV 
The activation of cellular immunity following an RSV infection is due mainly to 
epithelial cells and alveolar macrophages. Infants with a primary RSV infection often 
develop a cellular immune response within 10 days 124. Human cytotoxic T cell 
lymphocytes (CTLs) recognize the N, SH,F, M, M2 and NS2 proteins but not the G 
prote in 50. In mouse models, specifically in BALB/~ mice, the first cells to appear are the 
natural killer (NK) cells' followed by CD8+ cytotoxic T ce Ils, which may further 
modulate the immunity by secreting cytokines, especially IFN-y 124, 125,126. These CTLs 
predominantly target the M2 prote in followed by the Fand Nproteins 127,128. Both CD4+ 
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and CD8+ T cells have been demonstrated to have antiviral activity on passÎve transfer to 
RSV infected mice andreduce pulmonary shedding of the virus. However both cell types 
1 . d '1 d 129 a so cause lllcrease pu monary amage . 
The response to RSV by helper T (Th) cells has also been evaluated in the airWays of 
RSV-infected patiènt,s 130, 131. T cells pro duce pro-inflam~atory mediators c1assified as 
type 1 (Thl) or type 2 (Th2) cytokines. Thl cells secrete IL-2, IFNyand lymphotoxin, 
whereas Th2 cells produce IL-4, IL-5, IL-6 and IL-13 m. Increase in disease severity is 
associated with enhanced' T cell responses 133, as observed in the mouse model for RSV 
bronchiolitis, where prior sensitization with a formalin.,.inactivated RSV vaccine leads to 
a helper Th2-driven augmented disease, contrasting with the usual Thl response seen in 
primary viral infections 134. Individuals who have deficiencies in cell-mediated immune 
responsiveness have been shown to develop an unusual'but severe form of RSV infection 
with prolonged proliferation of the virus in the respiratory tract and progressive 
pneumonia 135. Of note, wheezing was not a major part of the clinical manifestations in 
these immunodeficient patients. These crucial data provide evidence that cell-mediated 
responses are important in terminating RSV infection and that cellular immunity may 
contributeto the development of wheezing after RSV infection and the severity of the 
disease. It is apparent that cell-mediated immunity is ari important component in a 
patient's response to RSV infection, as well as in his/her recovery. 
2.6 CURRENT TREATMENTS AND PROPHYLAXIS 
Despite growing concems over this problem, to this day, after almost five decades of 
effort, no effective and r.eliable vaccine or preventive antiviral against RSV exists 6, 21,136. 
Currently, treatment of RSV infection is supportive which involves ensuring adequate 
fluid intake, providing supplemental oxygen, and sometimes, administering 
bronchodilators. In some cases of severe illness and/or high-risk patients, the broad-
spectrum antiviral drug ribavirin (Virazole) may be used in aerosolized form. Ribavirin, a 
synthetic guan6sine analog with the empirical formula CsH12N40 S (Figure 4), was 
approved and licensed III 1985 to be delivered Via small-particle aerosol for use in 
hospitalized children in the United States 137. The mechanism of action of its antiviral 
properties remains unknown, however it was shown that ribavirin inhibits of the synthesis 
of viral structural proteins, thereby slowing viral· repli cation and also resulting in a 
reduced IgE response 138. Although ribavirin is the only anti-viral preparation approved 
for RSV infections, the use of this teratogen is· still controversial as it has not 
demonstrated significant reduction in either hospitalization or mortality rates 139, 140. 
Furthermore, due to its very labor-intensive administration methods and its potential 
hazardous effects on the caregivers 7, its use has been questionedon economic and safety 
grounds. 
Figure 4. Structural formula of ribavirin. Ribavirin is a synthetic guanosine analog. It has an empirical 
formula of C8H12N405. Figure modified from (Domachowske, 1999) 35. 
Prevention of RSV infection by passive administration of antibodies on the other hand is 
tremendously expensive thus is restricted solely to high-risk infants (defined ,by 
prematurity, immunocompromised status, or pre-existing pulmonary disease). There are 
currently two forms of anti-RSV antibody prophylaxis available on the market: RSV-
IGIV and palivizumab. RSV-IGIV (RespiGam; Medlmmune, Gaithersburg, MD) is 
produced with pooled serum fromhuman donors with high titers of antibody against RSV 
4. It has been shown to significantly reduce hospitalization rates for high-risk infants 
when administered intravenously once a month at a dose of 750 mg/kg for each month of 
the peak RSV season. However due to the high cost and the complications associated 
with the intravenous administration, the cost-effectiveness of this product has become 
questionable 4, 5. In 1998, Medlmmune introduced palivizumab (Synagis), a humanized 
monoclonal antibody directed against the F protein. Palivizumab is administered 
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intramuscularly, at a dose of 15mg/kg, 50 fold lower th an RSV-IGIV, yet appears tohave 
similar efficacy in the reduction of RSV hospitalization rates. However, lik~ RSV -IGIV, 
the co st for the injection of palivizumab is high. With this basis,. revised guidelines for 
RSV prophylaxis limits its administration to infants with chronic lung disease, infants 
born earlier th an 33 weeks gestational age, or later-term premature infants with at least 
one other risk factor 6. 
Therapeutics 
Oxygen 
~2 agonist 
Racemic Epinephrine 
Aerosolized 
recombinant human 
DNase (Pulmozyme) 
Inhaled and systemic 
corticosteroids 
Nasopharyngeal 
suctioning 
. Helium-Oxygen gas 
mixtures (Heliox) 
Inhaled Nitric Oxide 
Extracorporeal 
membrane 
oxygenation 
Ribavirin 
Function & Results 
Used in cases where patients exhibit the typical signs of lower respiratory tract 
infection. The supplemental oxygen should be administered to maintain a 
saturation of >92%. 
Used to treat wheezing, frequently present in HSV infections. However, despite 
numerous clinical trials, the effectiveness ofthis therapy rerriains questionable. 
Given either via injection or nebulized to ameliorate the symptoms of RSV 
infection. Racemic administration may improve oxygenation, respiratory distress 
score, and pulmonary function measures in majority of the cases. . 
After DNase administration, chest radiograph scores improved significantly, 
however, other measures such as improvement in respiratory rate, wheezing, and 
retractions during hospitalization did not. Thus concluding that the effectiveness of 
this treatment is doubtful. 
Prescribed for the treatment of bronchiolitis, both during the acute phase and 
during the period of recurrent wheezing that follows RSV infection in many infants. 
Studies have shown that the anti-inflammatory action of the corticosteroids should 
provide effective therapy for infections, however its efficacy Jor RSV remains still 
unclear. 
Defined as extending a suction catheter up through the nose, passing the tip to the 
hypopharynx, and then applying suction as the catheter is withdrawn. An 
exceptionally effective palliative measure for infants with RSV by clearing the 
secretions present in the nose, pharynx and lower airways to improve the 
resistance of breathing and provide some symptom reJief .. 
Functions by decreasing the work of breathing and by improving gas exchange in 
obstructive conditions (i.e. croup and chronic obstructive pulmonary disease).· 
Studies have shown that this may be useful in avoiding respiratorY failure and 
intubation in RSV-infected infants. . 
Currently approved by the United States Food and Drug Administration for the 
treatment of persistent pulmonary hypertension of newborns only. Given to treat 
severe RSV pneumonia and bronchopulmonary dysplasia and may improve 
oxygenation and respiratory system resistance. 
A suitable option for patients with severe RSV disease who cannot be supported 
on mechanical ventilation. 
A synthetic nucleoside (guanosine analog) and the sole anti-viral preparation 
currently approved for the treatment of RSV infections. While the mechanism of 
action of its antiviral properties remains unknown, it may act by inhibiting RSV 
replication during the active replication phase of the virus. 
Table II. Current therapies for RSV infections and their functions. Despite almost five decades of 
research, no effective and reliable vaccine or preventive antiviral against RSV exists. Currently, treatment 
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of RSV infection is supportive, such as the administration of supplemental oxygen, ~2 agonist, racemic 
epinephrine, aerosoli:.;:ed recombinant human DNase, inhaled and systemic corticosteroids, helium-oxygen 
gas mixtures, inhaled nitric oxide, suctioning of the nasopharyngeal regions, and oxygenation of the 
extracorporeal membrane oxygenation. The sole antiviral drug available is Ribavirin, whose use is reserved 
for persons at high risk for severe disease 95. 
Different approaches have been developed for RSV infections (Table II), however no 
effective treatment beyond palliative measures has yet appeared· 95. With very few 
therapies available for RSV infectioI?, more research is needed to find effective measures 
to prevent or treat RSV infection. Although the disease is self-limited by the body's own 
. immune response, the persons most susceptible to severe infection which inc1ude 
immunocompromised patients, infants, elderly, and bone marrow transplanted patients 
are those individuals who are the least capable of coping with an infection. Ultimately, 
prophylaxis is the most effective way to handle the infection and a novel technology , 
termed RNA interference may be the answer to treat an infection during epid,emics or 
once established. 
CHAPTERIII 
RNA INTERFERENCE AND siRNAS 
FOR THE THERAPY OF RSV INFECTION 
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3.1 RNA INTERFERENCE 
The discovery of the structure ofDNA by Watson and Crick in 1953 is considered to be 
one of the most important scientific breakthroughs in the last century 141. Through their 
model of the DNA structure, genetic information was described as being coded along the 
. -
polymeric DNA molecule composed of only four types ofmonomeric units, which were 
'orga~ized into genes, and that DNA m'olecules are the basis of heredity 142, 143. Genes 
were described as controlling the synthesis of various types of RNA, most of which were 
involved in the process of protein synthesis 144. 
Since a11 genomes of complex organisms are pote,ntial tatgets of invasion by viruses and 
transposable elements, gene therapy seems to hold tremendous potential in the treatment 
of the many genetic and acquired diseases. Although there are many nucleic acid drugs 
currently on the market and in production, recently a growing interest has been placed on 
. , 
RNA interference (RNAi) as a potential therapeutic agent for silencing numerous viral 
infectious (gene~ r~quired for viral repli cation) and cancer genes (oncogenes). 
3.1.1 Nucleic acid drugs 
The majority of cutrently employed pharmacological approaches for modulation of gene 
function rely upon the interaction of low molecular weight chemical compounds, such as 
nucleic acids, targeting proteins so as to qown-regulate the function of the( proteins 
themselves. Nuc1eic acidsmay be defined as. the macromolecliles in which the 
nucleotides remain linked to each other by phosphodiester bonds between the 3' - and 5'-
positions of the sugars 145. These macromolecules control metabolism throughout the life 
of a cell by directing and regulating prote in and enzyme synthesis and are key elements 
in transferring genetic information from one offspring to another. These charaçteristics 
can be taken advantage when developing drugs targeting cancer or infectious dis'eases. 
./ 
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There are five major classes of nucleic acid drugs which are' categoJÏzed based on their 
target site and mechanism of action: aptamers, .antisense oligonucleotides (ASONs), 
ribozyme nucleic acids, antigene nucleic acids, and RNA interference (Table 1). 
, 
Nucleic acid drugs 
Aptamers 
Ribozyme nucleic acids 
(Catalytic RNAs) 
Antigene nucleic acid 
compounds 
Antisense oligonucleotides 
(ASONs) 
RNA interference 
Properties & function 
Single or double stranded nucleic acids. 
Selected and amplified oligonucleotides that have been isolated from random pools of 
synthetic oligonucleotides, based on their ability to bind with high affinity to biological 
target molecules . 
. Bind to proteins involved in the regulation and expression of genes dependent upon 
activity of protein. 
Stable under various buffer conditions. 
Resistant to harsh treatment such as physical or chemical denaturation with no loss of . 
activity: 
RNAs that caialytically cleave covalent bonds in a target RNA. 
The catalytic site is the result of conformation adopted by the RNA-RNA complex in 
the presence of diva lent cations. 
Fairly unstable against nucleqlytic degradation, leading to conformation al changes 
that abolishes the catalytic activity. 
Challenges in their delivery to target cells. 
Nucleic acids that bind to single stranded or double stranded DNA. 
Binding occurs at a replication or transcription bubble, thus interfering with the 
transcription process. . 
An oligonucleotide with a sequence complementary to the target gene mRNA. 
Functions by binding to ihe mRNA of the target gene and blocking translation of the 
message into protein. 
The antisense may also bind to DNA in the nucleus, blocking transcription or to the 
transcript during its processing and transport from the nucleus to the cytoplasm. 
Designed to prevent or at least reduce the expression of a specific target gene. 
Unmodified antisense oligonucleotides are often unstable and rapidly degraded by 
nucleases. 
Initiated by long double-stranded RNA molecules, Which are processed into sm aller 
sized RNAs by the enzyme Dicer. 
The small RNAs th en degrade the target RNA with a nUclease, by incorporating itself 
into the RNA-induced silencing complex (RISC), a protein-RNA complex. 
Challenges in the stability and delivery to target cells. 
Table I. The Cive major classes of nucleic acid drugs. Nucleic acid-based molecular therapeutics, such as 
aptamers, ribozyme nucleic acids, antigene nucleic acid compounds, antisense oligonucleotides, and RNA 
interference, can down regulate the expression of certain target genes. However, issues with potency, 
specificity, and delivery in most classes of nucleic acid drugs, scientists have tumed to RNAi for means of 
solving these obstacles 145. 
Among the promising therapeutic. approaches, antisense oligonucleotides have been 
vigorously pursued as a therapeutic strategy for over 20 years. The progress, however, 
has been particularly slow because of problems with delivery to the target çells, stability, 
specificity and toxicity. Antisense oligonucleotides are short (~20 base) nucleic acids, 
designed to be complementary to the target RNA sequence in order to bind to the target 
and to limit the consequence of RNAby obstrueting the production of proteins 146. This 
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gene selectivity enables taigeted drug design and therefore the production of more 
effective and less toxic therapeutics. However, recent discoveries of RNA interference 
have had immediate and widespread impact 147, 148. Once evidence that double-stranded 
short synthetic RNAs can inhibit gene expression in cultured mammaliaIi cells, a surge of 
experimentation resulted, affecting virtually every field of biological science. Similarities 
exist between RNAi and antisense oligonucleotides 146 such as· their length, their 
complementarity to target the mRNA and their methods of synthe sis, however there are 
advantages to RNAi over ASONs that will be described in greater length in the 
subsequent sections. 
3.1.2 Discovery of RNA interference 
RNA interference is a naturally occurring, sequence-specific 1 mechanism for gene 
silencing. It is thought to silence viruses and rogue genetic elements that make double-
stranded RNA (dsRNA) intermediates (types of RNA but not usually produced bycells). 
Napoli and Jorgensen were the first to observe the mechanism of gene silencing in plants 
in 1990. Two years later, Romano and Macino reported a similar phenomenoIi in 
Neurospora crassa 149. Then in 1997, evidence that RNA could elicit gene silencing in 
animal cells came from the work by Guo and Kemphues, who ciemonstrated .that sense 
RNA was equally effective in reducing gene expression in the nematode Caenorhabditis 
elegans as was an antisenseRNA 150. At the time, these observations were puzzling, 
however they were readily understood when Fire and Mello's work was published in 
1998. Fire and Mello detailed the phenomenon of RNAi and discovered that very small 
amounts of dsRNA(the combination of sense and antisense RNAs) was ten-fold more 
effective than either RNA strand al one 147. This observation of interference was further 
explored by several leading groups including Baulcombe, in plants as part of post-
transcriptional gene silencing 151 and summarized by Sharp 152. It was these findings that 
led to the realization that RNA was responsible for the "hornology-dependent gene 
silencing" phenomena observed adecade ago and initiated the cascade of research on 
RNAi in a variety of organisms including plants, fungi, flies, worms and also complex 
mammals 147, 152,153,154,151,155,156,157,158,159,160,161,162, 163, 164, 165, 166 
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3.1.3 Types of RNA interference 
RNA interference is initiated when dsRl\lA is processed intosmall RNAs of 21-23 
nucleotides (nt) in length by the intracellular RNase III enzyme Dicer 167. These small 
RNAs are then incorporated into the RNA-induced silencing complex (RISe) within the 
cytoplasm of cells, which acts as a guide to the complementary nucleic-acid targets 
resulting in cleavage of the target RNA (Figure 1). Two relatively well-defined classes of 
small RNAs are involved in RNA silencing: microRNAs (miRNAs) and small interfering 
RNAs (siRNAs) (Table II, shaded in yellow). Because the active forms of miRNA and 
siRNA are sometimes biochemically or functionally indistinguishable, they are classified 
based on their onglnS, their evolutionary conservation, and the types of genes they 
silence. 
Type of RN Ai 
MicroRNA 
(miRNA) 
Small interfering RNA 
(siRNA) 
Tiny non-coding RNA 
(tncRNA) 
Small modulatory RNA 
(smRNA) 
Characteristics and properties 
A class of 19--25-nt single-stranded RNAs. 
Encoded in the genomes of most multicellular organisms studied. 
Some are evolutionarily conserved and are developmentally regulaled. Undergoes a !wo-
step cleavage of hairpin precursors by Iwo RNAse III enzymes, Drosha and Dicer. 
Elicit translational repression and mRNA cleavage. ,., 
A class of double-stranded RNAs of 21-24 nt in length. 
Generated from the cleavage of long dsRNAs by Dicer. 
Gene silencing by mRNA cleavage, by histone and/or DNA modification, or by histone 
methylation leading to DNA elimination. '" ' 70 m on on 
A newly discovered class of short, 20-22-nucleotide RNAs. 
Encoded in the genome of C. elegans. 
Not evolutionarily conserved, but some are developmentally regulated. 
Produced by Dicer from unidentified precursor. 
Func!ion still unknown. 174 
A short -20 nucleotide dsRNA, identified in 2004 in mice. 
Allows the expression of neuron-specific genes only in adult neurons. l7S 
Table II. Various types of RNA interference and their main characteristics. Modified from Novina 
(2004) and Kim (2005) 176 177. 
MiRNAs, previously named small temporal RNAs (stRNAs), were first discovered in 
C h bd" 1 . 1993 178 179 180 181 M'RNA d RNA aenar a ztIS e egans ln ,... 1 S are en ogenous s, 
generated from the non-protein-coding dsRNA region of the hairpin-shaped precursors 
while siRNAs are derived from long dsRNAs. Whereas miRNAs derive from loci that are 
unique for a diverse range of other recognized genes, endogenous siRNAs are often 
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occurring and originate from transposons 170, 182, 183, 184, and viruses that producedsRNA 
during repli cation 173, as well as other types of bi-directionally transcribed repetitive 
. sequences 185, 186 and genes 173, 174. White miRNA sequences are nearly always conserved 
among related organisms, endogenous siRNA sequences are rare1y conserved. 
Furthermore, miRNAs "hetero-silence" genes that are very different from their own 
origination, whereas, endogenous siRNAs"auto-silence" genes at the same locus, or very 
similar loci, from which they originate. 
3.2 SMALL INTERFERING RNA 
The discovery of siRNA was first ohserved in 1999 by Hamilton and Bau1combe 151 
followed by the demonstration that synthetic siRNAs induced RNAi in mammalian cells 
by Tuschl et al in 2001 187, leading to arise ininterest in employing RNAi for biomedical 
research and drug development. 
3.2.1 Silencing pathway 
The siRNA pathway begjns. with the c1eavage of long dsRNAs by Dicer enzyme 
complex, a member of the RNase III superfamily of endonuc1eases, intosmall fragments 
of 21-24 nt in length with 3'-overhangs 151, \166,188, 189, 190 (Figure 1). A multi-enzyme 
complex, which inc1udes the RISC and Argonaut~-2 (AG02, also known as EIF2C2), a 
protein that cari bind small RNAs 191 and in sorne cases execute target-mRNA c1eavage 
\92 \93, bind to the siRNA duplex and discards the passenger(sense) strand to form an 
activated complex containing the guide (antisense) strand. The siRNAs guide this AG02-
RISC nuc1ease complex in search of èomplementary target mRNA sequences. Once the 
antisense or guide strand is of perfect or near perfect complementarity to the target 
mRNA xesulting from the specificity dictated by base-pairing interaction between guide 
and target RNA strands 166,189, 194, the complex then c1eaves the mRNA strand (carried 
out by the catalytic domain of AG02) between the nuc1eotides that are complementary to 
nuc1eotides 10 and 11 of the guide strand relative to the 5' -end (Figure 1). Cleavage of 
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the target rnRNA results in the prevention the synthesis of proteins and reduction in the 
level of the proteins. 
m7G ............ 1M 
siRNA-medlated 
brget recognition 
RISC 
...In'" slRNA duplex 
(21-23merl 
~ slRNAproteln . complu (sIRNPI RISC activation 
ADP+ Il ATP 
............. -. .......... (AI. mRNA 
a-vage of brgeted 
mRNAbyRISC 
Recydlng 
m7G """" , , , , , , , , , , ft " (A J. --~) Gene Siiencing 
Figure 1. Silencing pathway of synthetic siRNA. Once inside the cel!, the siRNA is bound by proteins of 
the RNA-induced silencing complex (RISC) 195 148 196 to fonn the siRNA prote in complex (siRNP). The 
siRNA then guides the RlSC proteins in search of RNA sequences that are complementary to one of the 
two strands of the siRNA duplex in the genome. The sense or passenger strand dissociates from the 
complex, while the antisense or guide strand is matched with its complementary RNA target. Recognition 
of mRNA by the antisense strand of the siRNA results in the cleavage and destruction of the target mRNA, 
prevention of protein synthesis, and a reduction in the level of protein inside cells. Figure modified from 
(Novina 2004) 176 
While double-stranded RNAs larger than 21-23 nt in length rnay be appropriately Diced, 
it has been dernonstrated that dsRNA longer than 30 nt triggers a non-specific interferon 
pathway through interaction with the protein kinase PKR 197 and 2',5' -oligoadenylate 
synthetase 198) rather than RNA interference. Therefore chernically synthesized siRNA 
duplexes are generally ~21 nt in length such that they bypass Dicer and can induce RNAi 
by incorporating directly onto the AG02-RISC cornplex 199, 200, 201 (Figure 1), thereby 
potentially elirninating the PKRlinterferon response (see below) 187,202. 
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3.2.2 Non-specifie off-target éffects 
Despite having deveioped an understanding of the key players and mechanisms involved 
in RNAi, a. significant hurdle remains in the development of RNAi into a research and 
therapeutic tool,mainly the non-specifie off-target effects. Two types of off-target effects 
need to beavoidedor. minimized: silencing of genes sharing partial homology to the 
si RNA (off-targeting), and immune stimulation stemming from the recognition of certain 
siRNAs by the innate immune system. 
Although siRNA-mediatdd mRNA down-regulation was initially reported to be highly 
specifie 203, 204, 205, siRNAs can also recognize and interfere with the expression of certain 
mRNAs that share partial homo16gy with the target mRNA. Therefore it was not 
surprising to find that many of the off-target genes that have reduced mRNA levels 
contained regions that are complementary to one of the two. strands in the siRNA duplex 
using in vitro transcriptional profiling 206, 207, 208. Complementarity between the 5' -end of 
the guide strand and the mRN A is key to off-target silencing with the critical nuc1eotides 
being!n positions.two to èight (from the 5' -end of the guide strand) 209, 210. 
It was also noted early on tha~ siRNAs seemed highly specifie, as a single mutation in the 
target site could completely interfere with the silencing .187. Furthermore, as the first 
microarray experiments demonstrated excellent specificity for siRNAs 203, 204 it was not 
noticed that mutations in·the target region corresponding to the central region of several 
siRNAs did not always abolish RNAi 211. Severallater reports demonstrated that a single 
nuc1eotide mismatch between the siRNA strand and the target mRNA greatly decreased 
the rate of target mRNA cleavage 212,213,214; It was then that Jackson et al. revealed that 
siRNAs with only partial complementarity to mRNAs could also elicit gene silencing 206. 
These effects were. observed both for sense and antisense siRNAs. These silencing effects 
were evidently not related to the nonspecific interferon effect, as was observed for both 
. siRNAs 215 and short'hairpin RNAs 216, but dependent on the'sequence of the siRNA. 
This type of mRNA regulation was then coined the term "off-target" effects and is 
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typically associated with less than two-fold mRNA down-regulation 205, 206, 207, 209, 210, 217, 
218,219,220,221 
Other reports have shown that siRNAs may indeed induce sequence-specific off-target 
effects as described, however if they contain certain sequence motifs and structural 
features, nonspecific activation of the innate immune system, including induction of 
interferon pathway proteins, may be the result 222, 223, As mentioned previously, although 
dsRNA of 21-23 nt can be expected to avoid inducing the interferon response, it has been 
shown that at high concentrations, even these smaller siRNAs may be able to activate this 
pathway, resulting in global translational blockade and cel! death. Perhaps of greater 
concern is the potential to activate TLRs, especially the dsRNA receptor TLR7 in 
plasmacytoid dendritic cells, which in turn leads to the production of type I interferons 
and pro-inflammatory cytokines, and induce NF-KB activation 223. Interferon induction 
by sorne siRNAs occurs principally through TLR7, which is largely found in endosomes 
of immune antigen-presenting cells. Fortunately, TLR7 binding is highly sequence 
specific, favoring GU-rich sequence and can be fairly easily avoided by selecting and 
designing sequences that are not recognized by this receptor. 
3.2.3 SiRNA selection and design 
A synthetic siRNA consists of a 19 base-pair double-stranded reglOn that is 
complementary to the gene of interest, contains 5' phosphate and 3' hydroxyl termini, 
and possesses two single-stranded nucleotides on the 3' ends 187 (Figure 2). 
3' 
Double 
overhang 
Cleavage Seed region 
site 
Double 
overhang Passenger or 
sense strand 
Guide or 
antisense strand 
Figure 2. Schematic illustration of important features of siRNA structure. A basic siRNA is composed 
of two base pair overhangs, a seed region and an rnRNA c1eavage site. Figure modified from (de 
Fourgerolles, 2007) 224. 
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AI~hough there are currently no reliable methods to identify the ideal sequence for a 
siRNA, a number of general guidelines have been suggested by Tuschl et al 225 and also 
various company synthesis protocols, such as Dharmacon, QIAGEN" and Ambion. 
Selection of a target mRNA region should be within 50 to 100 nucleotides downstream of 
the' start codon. A 23-nt long sequence should be selected from the 'mRNA conforming to 
the consensus 5'-AA[N19]UU-3' or 5'-NA[N19]NN-3', where N is any nucleotide. 
Sequences with Ge content between 30% and ~O% would be i~eal, however highly G-
rich areas should be avoided. Aiso to be avoided are regions that are likely to bind to 
regulatory proteins, such as 5' -UTR, 3' -UTR and regions close to the start codon 225. 
Although one can follow these guidelines it is st,ill necessary to test seve~al siRNAs, 
targeting distinct regions within the gene of intere,st, because there is great variability in 
the capacity of an individual siRNA to induce silencing 226, 227. The search for more 
_ accurate, efficient siRNA selection has resulted in a number of new developments, such 
as their mechanism of delivery and modifications of the chemical structure of siRN As. 
3.3 DELIVERY AND MODIFICATIONS OF siRNAS 
SiRNA represents a powerful tool for specific gene silencing and many are being pursued 
as potential means to inhibit expression of clinically relevant genes in a wide array of 
therapeutic applications. Thus far, in vivo gene silencing approaches are very limited in 
the mammalian system. Nonetheless, a number of potential candidate genes, especially in 
viral infections, cancers and inherited genetic disorders but also in chronic inflammatory 
diseases such as auto immune arthritis, have been defined and successfully targeted in 
vitro 228, 229, 230. SiRNAs, aswith other oligonucle~tide-based therapies, face sorne key 
hurdles including delivery, cellular uptake and biostability. Initial works with siRNAs 
were undertaken with unmodified, naturalmolecules. It soon became clear, however that 
native oligonuc1eotides were subject to relatively rapid degradation and thus require the 
need for better modes of delivery and chemical modifications for in vivo applications 
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3.3.1 Delivery of siRNAs in vitro and in vivo 
Naked siRNAs are degraded by the activity of RNase nucleases in human plasma with a 
half-life of minutes 231, 232. Although direct injection of naked siRNA (unmodified or 
chemically modified) has proven efficacious in multiple contexts of ocular, respiratory 
and central nervous system disease 8, 233, 234, 235, 236, 237, 238, 239, they are rapidly excreted 
through the urine when administered into the blood stream. SiRNAs when formulated 
into different carrier systems for in vivo delivery they may be protected from nuclease 
digestion and last longer than naked siRNAs. Effective delivery is the most challenging 
obstacle in the development of RNAi as a broad therapeutic platform. Animal studies 
using siRNA have either used no additional formulation (naked siRNA) or have delivered 
siRNA formulated as conjugates, liposome/lipoplexes or as complexes with peptides, 
polymers or antibodies. Different siRNA delivery approaches have been utilized by many 
scientists and were able to achieve RNAi-mediated silencing both in vitro and in vivo 
(Figure 3). 
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FÏI!.ure 3. Delivery of small interfering RNAs. Different strategies have been used to deliver and achieve 
RNAi-mediated silencing in vivo (A) Direct injection of naked siRNA (unmodified or chemically modified. 
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(8) Direct conjugation of siRNA to a natural ligand such ~s cholesterol. (C) Aptamer-siRNA conjugates. 
(0) Liposome-formulated delivery of siRNA. (E) Antibody-protamine fusion proteins have beeh used to 
non-covalently bind siRNAs through charge interactions. The passenger strand and the guide strand are 
representedin blue and orange, respectively. Figure modified from (de Fougerolles, 2007) 224. 
lmproved nuclease-stability is essential for siRNA duplexes 'that are exposed to ~uclease~ 
rich environments (such as blood) and are formulated using excipients that they 
themselves do not confer additional nùclease protection. As might be expected in these 
situations, nuclease-stabilized siRNAs show improved pharmacokinetic properties in vivo 
240. In other situations, when delivering siRNA directly to less nuclease-rich sites (sùch as 
the lung) or when delivering siRNA in conjunction with delivery agents such· as 
liposomes (Figure 3); the degree of nuclease stabilization can be reduced significantly. 
Although the ability of an siRNA duplex to reach its target cell intact is vitally important, 
since it needs to overcome the blood vessel endothelial wall and multiple tissue barriers, 
whether nuclease protection confers a measurable benefit once an siRNA i~ inside the 
cell remains to be detennined. Finally, once the siRNA reaches the target cells, cellular 
uptake of those siRNAs and intracellular RNAi activity require efficient endocytosis and 
intact double-stranded siRNAs, respectively. Therefore various delivery methods have 
. ~een developed to counter this problem of biodistribution (Figure 3), however a broader 
and simpler approach would be shifting focus from systemic delivery to local. 
Local delivery involves administration of the siRNAs to a sm aller and potentially more 
protected area within the body and is a good strategy because it simplifies distribution, 
lowers the likelihood of adverse side effects, and reduces the amount and cost of the 
siRNA dose. An example of this approach would be airway delivery of siRNA for 
respiratory diseases. lntra-nasal administration of 'cationic liposomé-fonnulated siRNA 
specifically targeting the influenza virus RNA genome into mouse lung infected with the 
influenza virus significantly reduced lung virus titer in infected mice -and protected 
animaIs fro~ lethal challenge 241. However, in vivo delivery of siRNA with cationic 
polymer carriers' (i.e. PEI) is often associated with severe toxicity in the host and possibly 
the induction of nonspecific interferon response through the Toll-like receptor pathway, 
as previously discussed. . Therefore,' pulmonary siRNA delivery might require 
formulations without cationic carriers. Naked delivery of siRNA intra-nasally into the 
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lungs has been successfully employed by Bitko to Ïnhibit respiratory syncytial viral 
prote in P in lungs of mi ce, reducing the viral titers by up to 80% 8,9. 
Local delivery has important implications for the role of chemical modifications· to 
si RNA. However if the siRNA is systemically administered, there is a greater need for 
modifications because the obstacles in bio-distribution and the requirements for stability 
are much greater. N"evertheless, although chemical modifications might be less essential 
for local delivery than systemic delivery, it is still probable that they can significantly 
improve the properties of drug candidates and this possibility should be explored during 
development. 
3.3.2 Modifications of siRNAs 
As previously mentioned, naked siRNAs are degraded in human plasma with a half-life 
, of minutes 231, 232. Therefore to convert siRNAs into optimized drugs, prolonging the 
siRNA half-life, enhancing their stability, increasing their affinity with RNA and bio-
. distribution without jeopardizing biological activity is crucial 242, 243, 244; 245, 246, 247,248 and 
can be accomplished by chemical modification.· Many different types of chemical 
modifications have been developed to improve the in vivo properties of nucleic acids 249, 
250, 251 .. Each modification offers a different potential for tailoring the properties of 
siRNAs. They can be used alone or in combination and the number of modified 
nucleotides can vary relative tothe number that remain as unmodified RNA. The 
modifications also differ in how they are tolerated by the RlSe complex. Sorne 
modifications can be introduced at almost all bases of both RNA strands, whereas other 
modifications cannot be placed at sorne positions without interfering with efficacy. The 
modifications generally involve alterations to the ribonucleotide ribose ring or to the 
oligonucleotide phosphate backbone (Figure 4). 
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Figure 4. Structure of RNA and the nucleic acid analogs and chemical modifications. Modifications 
identified in blue. (A) Native RNA; (8) Phosphorothioate (PS) backbone linkage; (C) Boranophosphate 
(Bû) linkage; (D) 4'-thio modified RNA; (E) Locked nucleic acid (LNA); 2'modified RNA: (F) 2'-0-
methoxyethyl (2' -MûE) RNA; (G) 2' -O-methyl RNA; (H) 2' -Fluoro RNA; and (1) 2' -deoxy-2' -fluoro-j3-
D"arabinonuc1eic acid(F-ANA). Figure modified from (Corey, 2007) 252. 
The starting point for these efforts has been chemistries that are already in tise with 
antisense olignuc1eotide and aptamer therapeutics. For instance, the introduction of a 
phosphorothioate (PS) backbone linkage (instead of phosphodiester (PO)) ~t the 3' -end 
protects against, exonuc1ease . degradation and improves the half-life of the 
oligonuc1eotides in circulation by increasing their binding to serum prote,in 253, 254, A 
phosphorothioate linkage is created by replacing a non-bridging oxygen atom on the 
1 
backbone phosphate between ribonuc1eotides with a sulfur atom 255 (Figure 4B). PS 
linkages have shown to retain their ability to silence target sequences when introduced 
into siRNAs according to several pub li shed studies 232, 240:256, 257,258, 259, 260, 261. Another 
alternative for modifying the phosphate backbone of an oligonuc1eotide is by replacing 
one of the non-bridging oxygen atoms with a boron atom to create a boranophosphate 
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(BO) linkage (Figure 4C). Although this modification has attracted relatively little study, 
preliminary researéh reported an improvement in gene silencing activity al lower 
concentrations relative to either PS siRNAs or native siRl'lJ"As and an enhancement in 
their resistance todegradation by nucleases 262. 
Various modifications can alsobe introduced to the ribonucleotide ribose ring, such as 
replacing the oxygen that is attached to the 4 'carbo'n of the ring with a sulfui atom 
generating a 4' -thio modified RNA (Figure 4D). By introducing this sulfur atom into the 
ribose ring within both sense and antisense strands of the siRNAs, their resistance to 
digestion by l nucleases was greatly enhanced 263, 264 and so was theirpotencies 264, 
Another modification to the ribose ring is by inserting a methylene bridge between the 2' 
and 4' carbons of the ribose ring 265, 266 and creating locked nucleic acids (LNA) (Figure 
4E). This methylene linkage "locks" the ribose ring into a conformation close to that 
formed by RNA after hybridization. By introducing this constiaint, it increases the 
thermal stability of the siRNAduplexes and also resistance to digestion by nucleases 243. 
Many RNA analogs have been developed. that include substitutions for the hydroxyl 
group on the 2' carbon atom of the ribose ring. These RNA analogs include 2'-0-
methoxyethyl (2'-MOE) RNA (Figure 4F) 267, 268, 2'-0-methyl RNA (Figure 4G) 269 
and 2' -fluoro RNA (Figure 4H) 270. Enhanced affinity of the RNA oligomers for, 
complementary RNA or DNA sequences and increased resistance'tn nuclease digestion 
has been reported with these RNA analogs 217, 232, 240, 243,256,257,258,259,260,263,264,271,272, 
273, 274, 275, 261 
Lastly, a relatively newer class of 2' modification is 2'-deoxy-2'-fluoro-~-D.,. 
arabinonucleic acid (F-ANA). F-ANA nucleotides are based on the sugar arabinose rather 
than ribose and have the stereochemistry at the 2' -position inverted relative to that found 
in 2'-O-methyl RNA and 2'-fluoro RNA (Figure 41). The characteristics and properties 
ofF-ANA modifications will be discussed in the following section. 
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3.4 F-ANA MODIFICATION~ OF OLIGONUCLEOTIDES 
Arabinonucleic acid (ANA) is a 2'-stereoisomer of RNA with the sugar ribose replaced 
by arabinose 276. When the ANA is further modified by substituting the C2'-OH group 
with a fluorine atom, 2' -deoxy~2' -fluoro-~-D-arabinonucleic acid (F -ANA) is created 
(Figure 5) 277, 278. 
~&M ~ .. 
. OH tçIa.: 
oJ-: 0 0 o=~-o' o ·~-O· 1 1 1 
0 0 0 
\r \:1~ \:17 . OH
OR'OH OR' OR' 
(A) RNA' (B)ANA (C) F-ANA 
Figure 5 Chemical structure of Ribonucleic and arabinonucleic acids. Inversion of configuration at the 
2'-position of (A) RNA and 2'-F-RNA gives the corresponding epimeric arabinonucleic' acids, (B) ANA 
and (C) F-ANA. Figure modified from (Corey, 2007) 252 and (Kalota, 2006) 277. 
ANA and the corresponding F -ANA were the first uniformly 2' -sugar-modified 
oligonucleotides reported to induce RNase H cleavage of a bound RNA molecule 279, due 
to their structural similarities to normal DNAIRNA duplexes 280, 281. Also, the 2'F-
\ 
substituent in F-ANA/RNA hybrid projects into the major groove of the helix, su ch that it 
does not significantly interfere with the binding and subsequence catalysisof RNA by 
RNase H 282, 283. By replacing the 2'-OH group with a smaller 2'-F atom, the resulting 
compound has a significantly enhanced binding affinity to the target mRNA compared 
with native or PS-modified DNA 284, 279. Vpon the incorporation of the "up" fluorine 
atom, the sugar becomes 'rigid' as a result of a strong effect between the 2'-F atom and 
the oxygen ring, causing the equilibrium to favor this newly formed conformation 285 
(Figure 5). 
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Various studies were conducted to compare the gene silencing efficiency of F-ANA 
modified siRNA and native siRNA molecules. Dowler et al had observed that the 
efficacy and stability oftheir siRNA could be greatly improved by strategic modifications 
with F-ANA, particularly when made in the sense strand together with modification of 
the 3'-overhanging end of the antisense strand, in vitro (Figure 6) 10. 
5' - - 3' 
3' -
- 3' 
3' -
FANA 
modification 
Figure 6. Example of the modifications of siRNA with F-ANA chemistries along either or both the 
sense and antisense strands. (A) Native 21-nt siRNA; (8) Two F-ANA modifications at the Y-end of the 
siRNA. 
Recent studies have shown that siRNAs with completely F-ANA-substituted sense 
strands are 4-fold more potent than analogous unmodified RNAs and have a longer half-
life in serum ID, 286. F-ANA substitutions can also be tolerated for gene silencing wh en 
placed at the 3' and 5' positions of the antisense strand or throughout the sense strand. In 
addition F-ANA substitution enhanced the resistance of the siRNA duplex to degradation 
in serum containing medium, a property that may impact upon the future therapeutic 
development of chemically modified siRNAs. However, their improvements capabilities 
in vivo are still unknown, and will be explored in further on in this document. 
3.5 APPLICATIONS OF siRNA IN RSV DISEASE 
As previously mentioned, hRSV is the leading cause of severe lower respiratory tract 
disease in infants and young children throughout the world. hRSV disease in the young 
has been linked to the possible development of asthma later on. A lot of research has 
been conducted on finding prophylaxis and vaccine but has been thus far quite 
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unsuccessful. However a newcomer, siRNA, has great potential in this domain. Many 
researchers have shown to inhibit various viruses with the use of siRNAs. Bitko and 
Zhang were able to establish inhibition of the hRSV in their mousé models 8, 9. Bitko's 
research focused on the inhibition of the polymerase P gene of the hRSV, responsible for 
the viral replication and propagation. They infected with 107 PFU and transfected 
siRNAs intra-nasally at 70 !-tg intra-nasally per mouse and were able to obtain up to 99% 
inhibition of viral load in their results. Zhang and colleagues were also able to attenuate 
the virus by targeting the viral nonstructural NS 1 gene; speculated to also play a vital role 
in the replication of the virus. Zhang et al observed a substantial knock down of NS 1 
gene expression with lOg of siRNA plasmid with a nanochitosan polymer when 
administering intra-nasally ili mice infected with 5xl06 to lxI07 PFU ofhRSV. 
These findings combined with those from Dowler and Ferrari on F-ANA modifications of 
siRNA and ASONs, prompted us to investigate whether siRNAs modified with F-ANA 
would inhibit viral propagation and repli cation equally as well as or if so, even better than 
unmodified siRNAs. In this research project, we investigated siRNAs targeting both P 
and NSI genes, from the best siRNA sequences selected from Bitko and Zhang's 
research. 
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CHAPTERIV 
MATERIALS AND METHODS 
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4.1 CELL CULTURE AND MAINTENANCE 
A549 cells were maintained in Ham's Fl2K with 2 mM L-glutamine and supplemented 
with 10% of fetal bovine serum (FBS). HEp-2 cells were maintained in Minimal 
Essential Media with 2mM L,;,glutamine and Earle's BSS and with 100 U/mL penicillin, 
100mg/mL streptomycin, 0.1 mM non-essential amino acids and 1mM sodium pyruvate 
then supplemented with 10% of fetal bovine serum. ,Cells were' grown at 37°C in a 
humidified atmosphere containing 5% CO2• A549 (lung epithelial) and HEp-2 (larynx 
epithelial) celllines were obtained from the American Type Culture Collection (ATCC) .. 
4.2 VIRUS PROPAGATION AND PURIFICATION 
Human RSVtype A2, obtained from ATCC (#VR-1540), were grown on HEp-2 
monolayers and purified by plaque purification. HEp-2 cells are the recommended host 
cells for RSV propagation 287, 288, 289 (ATCC product description sheet for product VR-
1540). HEp-2 cells were seeded in tissue culture flasks and grown to ~80% confluency 
after an ovemight incubation. The cells were then rinsed with lx Phosphate-buffered 
saline (PBS), so as to remove traces of FBS, as it may interfere with .virus absorption, and 
th en exposed to 0.1 plaque forming units (PFU)/cell for 2 hours at 37°C, with agitation of 
the flasks every 15 ~inutes. Viruses were propagated at low multiplicity of infection (0.1 
MOI or less) to favor the amplification of the wild-type version of the virus rather than 
mutant viruses as wild-type viruses are expected to be more efficient at completing the 
viral life cycle. Followlng the incubation period, the cells were washed once more with 
1xPBS and then replaced with fresh infection mediuII!, (HEp-2 culture media with only 
2% FBS and no antibiotics). The cells were kept at 37°C, 5% CO2 and the infection was 
monitored daily for syncytia' formation and cytopathology by examining the cells 
microscopically, until greater than 75% of the cells were involved in syncytium 
formation and cytopathology. The cells and the cellular debris were then resuspended 
vigorously and centrifuged for 10 minutes at 1,000 g to rem ove the debris. As sugars, 
more specifically sucrose 290, 291, 292, stabilize RSV virus particles the slipematant was 
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adjusted to 10% sucrose final .Jith 50% sterile sucrose solution (EM Sciences) and stored 
at -80°C after flash freezing the aliquots in liquid nitrogen. This freezing method ensures 
no loss of titer over a six-month freezing period 292. 
With increasing virus propagations, the likelihood of generating mutant virus particles 
incapable of replicating themselves but able to bind target ceUs is greater. These mutant 
viruses can interfere with ceU attachment of fully competent virus particles 293, which can 
lead to a decrease of the titer of the virus preparations over time. To avoid this situation, 
plaque purification was performed to isolate efficiently replicating virus clones. HEp-2 
ceUs were seeded in tissue culture plates to obtain a ~80% confluency after an ovepüght 
incubation at 37°C, 5% CO2• CeUs were rinsed with lxPBS and incubated for 2 hours 
with hRSV in infection media at various PFUs/cell at 37°C, 5% CO2 with intermittent 
shaking. CeUs were rinsed once again with lxPBS, overlaid with 0.5% noble agar 
(Bishop Ca!1ada Inc.) in EMEM with 2% FBS and allowed to incubate at 37°C, 5% CO2 
for 4 days. On the day of cloning, 20 weU-isolatèd large virus clones were selected. These 
virus clones should be wild-type infedious hRSV particles but the possibility of isolating 
a super infectious hRSV mutant cannot be excluded. In order to minimize the likelihood 
and impact of such an occurrence, these high titer clones wete combined with infection 
media and incubated at room temperature for 4 hours. The selected cloned viruses were 
pooled, infected onto pre-"seeded HEp-2 ceUs and adjusted to 10% sucrose final with a 
50% sterile sucrose solution il} water for storage at -80°C after flash freezing in liquid 
nitrogen. The final preparations had titers in the range of 106_107 PFU/mL. , 
As a control, hRSV was inactivated by treatinghRSV to UV irradiation usmg the 
UltraLum UV cross-linking apparatus for 20 minutes at 0.12 Joules/cm2 on ice. 
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4.3 SiRNA AND siF-ANA SEQUENCES AND ANNEALING 
Zhang et al and Bitko et al both published siRNA sequences that exhibited inhibitory 
effects both in vitro and in vivo 8, 9. The nucleotide sequence for each si RNA selected 
from their research is as follows: 
Name Target siRNA sequence 
siRSV-P1 RSV-P 5'-CGAUMUAUMCUGCMGAdT dT-3' 
3'-dTdTGCUAUUAUAUUGACGUUCU-5' 
siRSV-P2 RSV-P 5'-CCCUACACCMGUGAUMUdTdT-3' 
3'-dTdTGGGAUGUGGUUCACUAUUA-5' 
siRSV-NS1 RSV-NS1 5'-GGCAGCAAUUCAUUGAGUAdTdT -3' 
3'-dTdTCCGUCGUUAAGUAACUCAU-5' 
siRSV-NS1a RSV-NS1a 5'-GUGUGCCCUGAUAACAAUAdTdT -3' 
3'-dTdTCACACGGGACUAUUGUUAU-5' 
siRSV-P1-Mi RSV-P 5'-CGAUMUACGACUGAAAUGdTdT-3' 
3'-dTdTGCUAUUAUGCUGACUUUAC-5' 
siRSV-P2-Mi RSV-P 5'-CCCUACACCGAGUMUAUAdTdT -3' 
3~TdTGGGAUGUGGCUCAUUAUAU-~ 
siRSV-NS1-Mi RSV-NS1 5'-GGCAGCAAAU CAUAUAGG UdT dT -3' 
3'-dTdTCCGUCGUUUAGUAUAUCCA-5' 
siRSV-NS1 a-Mi RSV-NS1a 5'-GUGUGCCCGUAUACAAAAUdTdT-3' 
3'-dTdTCACACGGGCAUAUGAUUUA-5' 
Table 1. Sequences of unmodified siRNAs. SiRSV-PI and siRSV-P2 were designed and tested by Bitko 
el al against the hRSV P protein 8 (shaded in yellow). The siRNA sequences were based on actual 
sequencing of the viral strains in their laboratory. SiRSV -NS 1 and siRSV -NS 1 a were designed according to 
the sequences by Zhang el al to target hRSV NSI protein 9(shaded in green). Mismatches (-Mi) were 
created with scrambling at various positions aJong the sequence. Sequences were purchased from 
University Core DNA Services from University of Calgary. 
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siF-ANAs were designed with modifications of the siRNA by replacing certain RNA by 
their 2'fluoroarabinosides. The RNAs that are replaced by F-ANAs were written in 
bold: 
Name Target siRNA sequence 
siRSV-P2 F3/0 RSV-P 5'-CCCTACACCAAGTGATAA TTT -3' 
3'-dtdtGGGAUGUGGUUCACUAUUA-5' 
siRSV-P2 O/F4 RSV-P 5'-CCCUACACCAAGUGAUAAUdtdt-3' 
3'-TTGGGAUGUGGUUCACUAUUA-5' 
siRSV-P2 F3/F4 RSV-P 5'-CCCTACACCAAGTGAT AA TTT -3' 
3'-TTGGGAUGUGGUUCACUAUUA-5' 
siRSV-NS1 F3/0 RSV-NS1 5'-GGCAGCAATTCA TTGAGTATT -3' 
3'-dTdTCCGUCGUUAAGUMCUCAU-5' 
sIRSV-NS1 OIF4 RSV-NS1 5'-GGCAGCAAUUCAUUGAGUAdTdT -3' 
3'-TTCCGUCGUUAAGUAACUCAU-5' 
siRSV-NS1 F3/F4 RSV-NS1 S'-GGCAGCAA TTCA TTGAGTA TT -3' 
3'-TTCCGUCGUUAAGUAACUCAU-5' 
siRSV-P2-Mi F3/0 RSV-P 5'-CCCTACACCGAGT AA TATA TT -3' 
3'-dTdTGCUAUUAUGCUGACUUUAC-5' 
siRSV-P2-Mi O/F4 RSV-P 5'-CGAUAAUACGACUGAAAUGdTdT-3' 
3'-TTGGGAUGUGGCUCAU UAUAU-5' 
siRSV-P2-Mi F3/F4 RSV-P 5'-CCCTACACCGAGTAATATATT-3' 
3'-TTGGGAUGUGGCUCAUUAUAU-5' 
siRSV-NS1-Mi F3/0 RSV-NS1 5'-GGCAGCAAATCAT AT AGGTTT-3' 
3'-dTdTCCGUCGUUUAGUAUAUCCA-5' 
siRSV-NS1-Mi O/F4 RSV-NS1 5'-GGCAGCAAAU CAUAUAGGUdT dT -3' 
3'-TTCCGUCGUUUAGUAUAUCCA-5' 
siRSV-NS1-Mi F3/F4 RSV-NS1 5'-GGCAGCAAATCATATAGGTTT-3' 
3'-TTCCGUCGUUUAGUAUAUCCA-5' 
Table II. Sequences of siRNAs modified with F-ANA. F-ANA modifications were made for siRSV-P2 
(shaded in yellow) and siRSV -NS 1 (shaded in green) at various positions along the siRNA strand s, 
denoted in bold. Mismatches (-Mi) were created with scrambling at various positions along the sequence. 
Sequences were purchased from University Core DNA Services from University of Calgary. 
Mismatches, denoted with a -Mi, were created with modifications at 3 to 6 positions in 
each strand for every siRNA and siF-ANA as controis. 
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AIl oligonucleotides were obtained commercially from the University of Calgary DNA 
Synthesis Laboratory (Calgary, AB). The siRNAs and siF-ANAs were purchased from 
the center already gel-purifie d, thus purity was not defined. The single,stranded siRNAs 
orsiF-ANAs were resuspended in RNAse-free H20, dosed by Spectrophotometry and 
adjusted to a final concentration of either 50 or 150 /lM. Equal molarity of each 
complementary strandswere combined with siRNA annealing buffer (Tris 250 mM, 
NaCl 500 mM in RNAse-Free H20 with pH 7.5-8.0) then incubated at 90°C for 1-5 
minutes before being allowed to gradually cool to below room temperature. Final 
concentrations of the annealed complex were either 20 or 60 /lM. 
4.4 SiRNA TRANSFECTION AND VIRUS INFECTION IN VITRO, 
) 
SiRSV-Pl, siRSV-'P2,siRSV-NS1, siRSV-NSla and \ contro1s (their respective 
mismatches) were diluted to equal concentration of O'.l/lg/uL and then further diluted in 
Opti-MEM to have final quantities of 0.05, 0.1, 0.2 and 0.4 /lg per reaction. 
Lipofectamine 2000 (Invitrogen, Burling, ON) reagent was diluted to a DNA : lipid ratio 
, 
of 1:3 and incubated at room temperature for 5 minutes. Equa1 volumes of siRNA and 
reagent werecombined and incubated for 20 minutes at room temperature to allow 
complex formation. A549 cells were then transfected drop-wise with this complex. 
Following an ovemight incubation at 37°C, 5% C02, the transfected cells were rinse,d 
with lxPBS and then infected with hRSVat an MOI of 1 (i.e. 1 PFU/cell) in A549 
_ infection medium (similar to A549 culture media with 2% FBS). Virus was incubated 
with the cells for 2 hours at 37°C, 5% CO2 with intermittent shaking, after which the 
media was removed and replaced with fresh infection medium for ovemight incubation. 
4.5 IMMUNOSTAINING PLAQUE ASSAY 
Four days following infection, supematant from infected A549 cells were harvested and 
serially diluted tenfold with A549 infection medium. HEp-2 cells, seeded from previous 
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day, were rinsed with 1xPBS to remove traces of FBS and ,the diluted A549 supematants 
were loaded onto the cens and anowed to adsorb for 2 hours at 37°C, 5% CO2 with 
intermittent shaking. Once the adsorption time of the virus has been completed, sterile 
noble agar mixture (as previously described) was overlaid onto the cens and anowed to 
solidify at room temperature. cens were incubated at 37°C, 5% CO2 for 4 days. 
On day of staining, the agar overlay was removed by aspiration and a fixing solution 
containing 4%formaldehyde (Sigma-Aldrich) in 1xPBS was. added for 15-30 minutes to 
the cens. The fixing solution was removed by washirtg with 1xPBSand then a blocking 
solution (5% bovine serum albumin (BSA) fraction V in lxPBScontaining 0.1 % Tween 
20 (PBS-t, purchased from Sigma)) was added for 2 hours to block non-specific 
absorption of other proteins. Following the incubation period, the blocking solution wils 
removed and the cens were incubated for 1 hour at room temperature with biotin-Iabeled 
goat anti-RSV antibody (Virostat) diluted 1:480 in 5%· BSA-lxPBS-t. Excess goat 
antibody was removed by performing three 5-minute incubations at room temperature. 
with 1xPBS. The cens were then incubated for 1 hour at room temperature with a 1:300 
dilution of streptavidin-alkaline phosphatase (Calbiochem) in 5% BSA 1xPBS-t. Excess 
streptavidin remnants· were removed by washing twice with 1 xTBS (Tris-buffer saline) 
for 15 minutes at room temperature., For the color reaction, BCIPINBT solution (Sigma-
Aldrich) was added to the cens and incubated at room temperature in the dark until 
desired coloration was achieved. 
4.6ANlMALS 
The study was approved by the Animal Ethics. Committee of Mispro Biotech Services 
(Montreal, QC). F emale BALB/c mice 6 to 8 weeks of age and weighing 14 to 18 g were 
purchased from Charle·s River Laboratories. Mice were maintairied in Mispro's animal 
facilities in· filter cages in a separate room. Mice were anesthetized via intraperitoneal 
administration of 0.15 mL of xylazine-ketamine mix (100 mg/kg and 10 mglkg. 
49 
respectively) prior to administration of siRNA or virus. At time of-sacrifice, mice were 
administered 0.2 mL sodium pentobarbital (45mglkg) followed by exsanguination. 
4.7 NASAL ADMINISTRATION OF siRNA AND hRSV 
For nasal delivery of siRNA, various amounts of siRNA were diluted in Opti-MEM to 
obtain a final volume of 50 ~1. hRSV was, diluted in 10% sucrose such that 50~1 
contained 5xl0s PFUs. Sham infection was performed with the same volume of vehic1e. 
While under anesthesia, the mice were inoculated intra-nasally, with the use of a 
micropipette, into a single nostril with selected siRNA and then followed by an infection 
into same nostril after a short period of restfor the animaIs. On day 3, 6 and 10 post-
infection, the mice were sacrificed as described above then BAL was performed and 
whole lungs were harvested. As a positive control, hRSV -infected mice were given 50 
, 
mg/kg/day of ribavirin subcutaneously daily. On day 6 post-infection, the mice were 
sacrificed, BAL was performed and whole lungs were collected for further analyses. 
4.8 BRONCHOALVEOLAR LAVAGE, WHOLE LUNG COLLECTION AND 
CELLCOUNT 
Bronchoalveolar lavage (BAL) fluid was collected by perfusing the bronchi and washing 
the lungs 5 times with 0.8 mL cold normal saline. Total volume recovered was 3.5-3.8 
, J 
mL per mouse. BAL fluid was centrifuged at 1600 rpm for 7 minutes at 4°C, and then 
. 1 
supematant was aliquoted and stored at -20°C until determinationof cytokine and 
chemokine measurements such mouse monokine induced by gamma interferon (mMIG) 
and tumor necrosis factor-alpha (TNF-a) by enzyme-linked immunosorbent assay 
(ELISA) kits alçmg with hRSV prote in , levels). The remaining BAL cens were 
resuspended in filtered RPMI-20%FBS and the viability of the cells was established by 
ViaCount (GUA V A). For subsequent differential cell analysis by microscopy, BAL cells 
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were cytospun onto slides using the Cytospin 3 (Shannon) and stained with Rema-3 stain 
(Fisher). Lungs were collected by opening the chest cavity and retrieving the whole lung 
that was then cut into 0.5 cm pieces. Lung specimens were immediately snap frozen and 
stored at -80°C for later examination oftarget niRNA levels by real-time'RT-PCR. 
4.9 ANALYSIS OF INTRACELLULAR CYTOKINE PRODUCTION IN CELL 
SUPERNATANT AND BAL 
Interleukin-8 (IL.,8), mMIG, TNF-alpha ELISAs were carried out according to 
manufacturer's protocol from the BD OptEIA TM Set Ruman IL-8 (BD Biosciences, 
Mississauga, ON), Mouse CXCL9/MIG DuoSet kit (R&D) and Mouse TNF-alpha 
CytoSets anibody pair system (Bio Source ) Tespectively. 
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4;10 PROTEIN EXPRESSION ANALYSIS BY hRSV PROTEIN ELISA 
ELISA plate wells were first coated with a coating antibody solution composed of 
unconjugated polyc1onalgoat anti-RSV an,tibody (Virostat, Portland, ME) diluted 1: 1,000 
in lxPBS and incubated for 90 minutes at 37°C followed by washing 3 times with 
lxPBS-t. Wells \vere th en blocked with 5% BSA in lxPBS (i.e. assay diluent) and 
incubated at room ·temperature for one hour after which wells were washed another three 
times with PBS-t. SeriaI dilutions of RSV for the standards and the diluted supernatant or 
BALF were dispensed into the wells and incubated overnight at room temperature. On 
the following day, signal detection began withfirst washing the wells with PBS-t 3 times 
. then the addition of detection antibody solution (i.e. biotin conjugated polyc1onal goat 
anti-RSV antibody (Virostat, Portland, ME) diluted 1 :20,000 in assay di1u~Qt). Wells 
were incubated with the detection antibody. solution at 37°C for 75 minutes then were 
, 
washed 3 times with PBS-t. Streptavidin horseradish peroxidase (HRP) diluted at 0.2 
~g/mL was applied to the wells and incubated for 45mins at room temperature followed 
'by three washes with PBS-t. Tetra Methyl Benzidine (TMB) (Neogen) substrate solution 
\ ' 
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was added and the color reaction was allowed to develop in the dark. The color reaction 
was stopped with the addition of 2N H2S04 and the signal was read within 30 minutes 
using the ELISA Microplate reader at 450 nm subtracting the signal detected at 540 nm. 
4.11 DETECTION OF VIRAL mRNA IN CELL LYSATES AND LUNG 
HOMOGENATES 
Total RNAs were extracfed directly by Qiagen RNeasy Kit (Qiagen, Mississauga, ON) 
from celllysates in RL T buffer with DNAse treatment carried out on column according 
to manufacturer's protocol, in RNeasy Mini Handbook. Whole lungs harvested from 
mice were homogenized with either the Polytron PT 1200 (Kinematics, Switzerland) or . 
the Precellys 24 (Bertin, France) in RL T buffer then RNA was extracted from the 
supematant using Qiagen RNeasy Kit. 
Quantification of RNA was performed using the Ribogreen fluorescent assay according 
to its product information sheet from Invitrogen-Molecular Probes. Fin<:tl concentration of 
1 !lg/!ll of total RNA was used to prepare cDNA. Reverse transcription was performed by 
adding a mixture of 1 OmM dNTPs, Random Hexamers in RNAse-free H20 withthe RNA 
samples, and heated at 65°C for 5 minutes. The reaction was put on ice for at least 1 
minute to allow the temperature to decrease to 25°C (since Random primers were used). 
A second mixture composed of 5X buffer, O.lM DTT, SSII-RT in RNase-free H20 is 
added to the reaction for a 20 !lI total aJ?d allowed to equilibrate for 10 minutes at 25°C 
. followed by 1 hour at 50°C until the first strand cDNA had been synthesized. 
Gene expression of target RSV P and NS 1 mRNAs was analyzed by real-time PCR with 
Roche Lightcycler®2.0 instrument using the LightCycler® DNA Master SYBR Green l 
kit (Roche, Laval, QC). 17 !lI of 5X Roche SYBR Green mix, 25 mM RSV primers (both 
forward and reverse) in RNase-free H20 was added to 3!l1 of diluted cDNA samples, and 
allowed to cycle at 57°C for 40 cyCles. Primers for RSV P and NS 1 mRNA (TibBioMol) 
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were based on RSV (Acc# M74568) according to Bitko et al and Zhang et al 's published 
research 8, 9 (Table III). / 
Target 
RSV-P 
Rsv-Ns1 
fo rwa rd 
reverse 
fo rwa rd 
reverse 
Primer sequence 
5'-CCCTTTTCT AAACTATACAAAGAAACC-3' 
5'-AGCAGATGTAGGTCCTGCACTTG-;3' 
5'-A TGGGGTGCAA TTC A TTGAG-3' 
5'-CAGGGCACACTTCACTGCT -3' 
Table III. Primer sequences. Targeted against RSV P and NS 1 genes. 
Ppib and ~2m were determined to be the optimal housekeeping genes for in vitro and in 
vivo experiments, respectively and the levels of RSV -P and RSV -NS 1 in samples were 
expressed as a ratio to the housekeeping genes. A calibrator and a negative control (i.e. 
RNase-free H20) were included in every PCR run. 
4.12 STATISTICAL ANALYSIS 
AH results are expressed as mean values for the groups analyzed ± 1 standard error of the 
mean (SEM) (error bars in graphs). Groups were compared to either their respective 
mismatches or to the hRSV-only control by Manl}-Whitney test Differences were 
considered to be significant at P < 0.05. 
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CHAPTERV 
RESULTS 
5.1 ESTABLISHMENT AND VALIDATION OF MEASUREMENT METHODS 
5.1.1. Establishing and maintenance of hRSV culture in human epithelial HEp-2 
. cells. 
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HEp-2 cells are host cells for RSV propagation as recommended by the ATCC and in 
numerous studies 288 287289. Our initial experiments were aimed to not only demonstrate 
that in our hands hRSV Was able to properly prdpagate on HEp-2 monolayers but also 
that immunostaining was a sensiti~e and straightforward method of counting virus 
plaques to determine titers (i.e. the "gold-standard"). In the presence of hRSV on the 
HEp-2 cells, immunostaining produces a dark purple precipitate (shown as a dark gray 
dot in the black and white Figure 1), whereas areas without syncytia formations are not 
detected by the assay. 
Figure 1. Detection of hRSV on HEp-2 monolayer by method of immunostaining. Confluent 
monolayers of HEp-2 cells were infected with hRSV strain A2. On day 4 post-infection (PI), the ce Ils were 
fixed then immunostained with a combination of goat anti-RSV antibodies Iinked to biotin and streptavidin 
conjugated to alkaline phosphatase. The virus plaques were visualized after the cells were incubated with 
BCIPINBT. An hRSV plaque detected is shown with arrow. Figure is representative of a single weil. 
Average titer of hRSV measured from dupliCates was found to be 1.99 x 107 PFU/mL. 
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However, because the hRSV preparation was made in house and may contain other 
molecules secreted during the infection process, UV -inactivated hRSV was used as a 
control. When the virus was treated for 20 minutes at 0.12 J/cm2, the UV rays completely 
abrogated viral repli cation (Figure 2 B). No hRSV plaques were detected on the HEp-2 
cells of the UV -treated virus preparation, while plaques were clearly visible when the 
virus preparation did not undergo an UV irradiation (Figure 2 A) to yield an estimated 
titer of2.7x108 PFU/mL. 
(A) (8) 
Figure 2. Propagation of UV-treated hRSV. (A) As a control, half of the viral preparation did not receive 
any irradiation and was incubated on ice. (8) The other half was subjected to a 20 min 0. 12 J/cm2 UV 
treatment on ice using the UV cross-linker apparatus (framed in red). Then, the titer of both aliquots was 
determined by plaque assay. The UV irradiated aliquot was assayed undiluted and at al : 10 and ) : 100 
dilution . The aliquot that was not UV irradiated was assayed at the following dilutions : 10-3, 10-4 and 10-5. 
Each dilution was perforrned in duplicate. 
These findings clearly demonstrated the usefulness of the immunostaining assay and as 
such this assay was used in subsequent studies. 
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5.1.2 Inhibition of RSV infection with ribavir'in 
Although the recommended ceIl host for hRSV growth is HEp-2 cells, the human lung 
epithelial cell tiné A549 have also been used for infection and has been optimized in our . 
laboratory for certain transfections with siRNAs. Therefore, in order to use this cell hne 
for transfection assays to inhibit viral propagation, we first had to determine the 
experimental conditions necessary to detect viral replication. Stability was also 
, investigated to determine the optimal storage conditions for re-suspended ribavirin, as no 
infor:mation on re-suspended ribavirin was available. A549 cells were exposed to hRSV 
as described in the methods and the immunostaining technique was used to determine 
viral propagation in this ceIl type. Experiments included treatment conditions wherè 
, A549 cells were treated with the anti-viral ribavirin, stored either at 4°e or -80oe, for 2 
. hours prior to viral ~xposure and maintained in ribavirin-containing medium aftervirus 
absorption. When treating infected cells with increasing doses of Ribavirin, a dose-
dependent response was observed in both the titer levels (Figure 3) and the protein level 
(Figur~ 4) with almost complete inhibition of RSV replication at the highest dose, under 
both storage conditions. However, at the 100 ~M dose, the ribavirin that was kept at 4°e 
appeared slightly more efficient (Figure 3). As for the lower doses, 50 ~M and 10 ~M, 
the titer decrease with ribavirin was similar between 4°e and -80oe, thus both storage 
conditions seem equivalent. Since ribavirin was stable after undergoing one freeze thaw 
cycle and the long-term stability of ribavirin at 4°e wasunknown, re-suspended ribavirin 
stored at -800e was used to carry out aIl future experiments utilizing ribavirin. 
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Figure 3. hRSV titer levels detected in A549 ceUs treated with ribavirin. A549 cells were treated for 
2hrs with ribavirin (10 flM, 50 flM or 100 flM final), stored either at 4°C or -SO°C, in duplicates. Following 
this treatment, the cells were infected at an MOI of 1 with hRSV strain A2 or MOCK infected with the 
same volume of vehic\e only. After a 2hr absorption, the virus inoculum was removed and fresh infection 
media containing ribavirin to 10 flM, 50 flM or 100 flM fmal was laid over the A549 cells. On day 3 Pl, the 
supematants from the infected A549 cells were recovered and analyzed by immunostaining plaque assay. 
hRSV titer expressed as mean :t SEM. 
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Figure 4. hRSV protein levels detected in A549 cells treated with ribavirin. A549 ce lis were treated for 
2hrs with ribavirin (10 flM, 50 flM or 100 flM final), stored either at 4°C or -SO°C, in duplicates. Following 
this treatment, the cells were infected at an MOI of 1 with hRSV strain A2 or MOCK infected with the 
same volume of vehicle only. After a 2hr absorption, the virus inoculum was removed and fresh infection 
media containing ribavirin to 10 flM, 50 flM or 100 flM final was laid over the A549 cells. On day 3 PI, the 
supematants from the infected A549 ce Ils were recovered and analyzed with hRSV ELISA. hRSV titer 
expressed as mean :t SEM. 
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5.1.3 Establishing infection of hRSV in A549 cells. 
As sti:lted in the previous section, both HEp-2 and A549 celIs have been able to efficiently 
propagate the virus,however as the main focus of this project is the inhibitionofthe virus 
with siRNAs, and the œIl lineoptimized for siRNA transfection was A549 cells, we 
determined whether the viral growth in A549 cens paralleled' the growth seen in the ideal 
HEp-2 cells. Monolayers of both ceLL lines were infected with increasing MOIs and 
immunostaining plaque assay was utilized on the infected supernatant 3 days post-
infection. Upon visual inspection, A549 cens were not as susceptible as HEp-2 cells to 
hRSV infection since the infection-mediated morphological changes and cell death were 
delayed in A549 cells relative to HEp-2 ceLLs. However, only in A549 ceLLs, and not in 
HEp-2 cells did the viral titer vary in a dose-dependent fashion (Table 1 and Figure 5). 
In A549 cells, the titer increased by 10-fold for every 1 0-fold increase in the MOI used to 
initially infect the cells, whereas in HEp-2 cells, there was a 10 fold increase in the titer 
of the cells infected with an MOI of 1 and 10 but the titer was of the same magnitude 
when comparing the cens infectedwith an MOI of 0.1 and 1. 
Experimental Condition PFUlmL SEM 
MOCK MOCK 0 0 
MOI of 0.1 2.76x104 1.26x103 
A549 
MOlof1 3.30x105 3.52x104 RSV 
MOlof10 3.46x10G 1.91x105 
MOCK MOCK 0 0 
MOI of 0.1 4.56x105 1.01x104 
HEp-2 
RSV MOlof1 5.99x105 4.86x104 
MOlof10 5.81x106 1.14x105 
Table 1. Titer measured by plaque assay on day 3 PI from supernatant. A549 and HEp-2 cells were 
either mock infected or infected with hRSV at an MOI of 0.1, 1 and 10 in triplicates. On day 3 post-
infection, the supernatant was used to determine the virus titer by immunostaining plaque assay, 
1 l, 
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Figure 5. Viral Hter measured by plaque assay on day 3 Pl from supernatant. A549 and HEp-2 cells 
were either mock infected or infected with hRSV at an MOI of 0.1, 1 and 10 in triplicates. On day 3 post-
infection, the supematant was used to determine the virus titer by immunostaining plaque assay. Seriai 
dilutionswere performed in quadruplicates and me ans were calculated with 10-3 the plaque counts ± SEM. 
We therefore concluded that A549 cells were a good cellular system to investigate hRSV 
replication. 
5.1.4 Determination of readout methods for measuring infection. 
Although viral load is most accurately assessed by immunostaining plaque assay, this 
procedure is highly time-consuming and in order to rapidly screen molecules that 
interfere with hRSV infection, a faster readout monitoring hRSV virus production was 
required. As such we investigated alternative readouts including assessment of viral 
protein levels by hRSV ELISA, secretion of cytokine (lL-8 and MIP-Ia) as assessed by 
ELI,SA, and viral mRNA levels by real-time RT -peR. 
Developing an ELISA to monitor viral prote in production off ers several advantages as it 
is faster than plaque assay, allows high throughput as it can be performed using asmall 
amount of material on 96-wellassay plates. First however, we needed to deterinine 
whether viral protein detection would correlate to thé level of virus replication. 
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Figure 6. hRSV protein levels detected with hRSV ELISA over time. Supernatant from A549 cells 
infecte,d at an MOI of 0, 0.1, 1 and 10 with 'hRSV were harvested on day 1, 2 and 3 post-infection. The 
samplès were diluted 1 :20 in assay diluent which was found to be the most appropriate for signal detection. 
Unconjugated goat polyclonal anti~RSV antibodies (coating antibody; Virostat) was diluted 1:1000, biotin-
conjugated polyclonal goat anti-RSV antibodies (detection antibody; Virostat) was diluted at 1 :20,000 and 
Streptavidin-HRP (Biosource) was diluted at 0.2 ug/mL in 5%BSAPf3S-t. hRSV prote in levels éxpressed 
as mean of duplicates :i: SEM. 
Using the E~ISA m~thod, hRSV prote in was not detected in mock-infected cens over. 
time, whereas hRSV infected cens exhibited an increasing dose-dependent response with 
each additional day (Figure 6). The ELISA was optimized under conditions such that 
A549 cens were infected with low MOIs between 1 and 5 and samples harvested either 
on day 2 or 3 post-infection. 
The response of cens to hRSV infection is also of great importance and can be examined 
by measuring specific cytokines secreted by the host cens as an indirect of method' of 
quantifying the viral propagation. Different groups have shown that RSV-infection of 
A549 cens can induce IL-8 production 294, 295, 296. One group in particular has shown that 
for A549 cens, there is an hRSV dose-dependent release of IL-8 295. Thus, IL-8 was 
verifted as a quantitative readout method of hRSV infection in A549 cens (Figure 7). In 
A549 cens, we observed that IL-8 release increased over time and with increasing MOI. 
61 
laooo 1101 PI 
.01 PI 
.03PI 
15000 
::i' 
E 12000 
..... 
~ 
.. 9000 • ~ 
.. 
10 ;:. l1OOO 
3000 
0 
MOCK 
Figure 7. IL-8 secretion levels detected by IL-8 ELISA over time. A549 ce Ils were either mock infected 
or infected with hRSV at an MOI of 0.1, 1 and 10 in duplicates. On days 1, 2 and 3 post-infection, the 
supematants were collected for IL-8 ELISA (BD Biosciences). Data expressed as mean ± SEM. 
In comparison to IL-8, another cytokine, MIP-l a was not detected in mock-infected cells 
over time (Figure 7). Assaying for MIP-l a by ELISA therefore yielded results that are 
easier to interpret without the potential for conflicting background cytokine levels. 
Assaying MIP-l a release via ELISA is a reliable readout for hRSV replication. This 
system will be most sensitive at detecting molecules interfering with hRSV repli cation in 
supematants collected on day 2 post-infection from A549 cells infected at an MOI of 1. 
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Figure 8. MIP-Ia secretion levels detected by MIP-la ELISA over time. Supematants from A549 ce Ils 
infected at an MOI of 0, 0.1,1 or ID were coUected on day 1,2 and 3 post-infection. The MIP-Ia content 
ofthese supematants was determined by ELISA (R&D). Data expressed as mean of duplicates ± SEM. 
62 
Measuring cytokine secretion levels by the infected cells is an indirect method of 
measuring viral propagation. In order to directly determine viral replication, examination 
at the mRNA level was also considered (Figure 9). hRSV viral mRNA levels in RSV-
infected A549 celllysates were assessed via real-time RT -PCR. Optimization of real-time 
RT-PCR method is crucial and determination of the primers for reverse transcription and 
housekeeping gene plays an important role. Two reverse transcription primers, Oligo dT 
and Random Hexamers, were examined in which no difference was observed between the 
levels detected, therefore either primer had the capacity for transcription. Potential 
housekeeping genes Ppib, ribosomal 18S and ~-actin were ail tested, however Ppib 
showed the least amount of variability between samples thus it was determined to be the 
optimal housekeeping gene for in vitro screening of hRSV P mRNA. Under such 
conditions, hRSV P mRNA was detectable by real-time PCR 24 hours post-infection. The 
optimal infection load appeared yet again to be at MOI of 1 (Figure 9). A dose-response 
was observed from MOI of 0.1 to 1 however; at MOI of 10 there is a decrease in the 
amount of hRSV P mRNA. This may possibly be explained by cell death caused by an 
overabundance of virus. Nonetheless, viral mRNA can be readily detected by real-time 
PCR at very low MOIs and was included as a reliable readout for hRSV propagation. 
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Figure 9. rnRNA levels detected by real-tirne RT-PCR. Cell lysates were harvested from A549 cells 
infected with hRSV at various MOls 24 hrs post-infection, in duplicates, and RNA was isolated with 
RNeasy kit. Reverse transcription was perfonned to make cDNA by Random Hexamers. Viral P gene was 
amplified by real-time PCR with the Qiagen kit using Ppib as the housekeeping reference gene. CP values 
were nonnalized against the housekeeping gene and expressed as mean :!: SEM. 
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In summary, A549 cells provided a suitable and valid cellular system to investigate hRSV 
replication since they exhibit a dose-dependent virus production, which can be monitored 
by assessment of either viral protein levels, IL-8 and MIP-I a release, and also viral 
mRNA levels. 
5.2 CHOICE OF APPROPRIATE siRNAS: 
5.2.1 Designing siRNAs and their mismatches 
According to research published by Bitko and Zhang, inhibition of viral replication can 
be achieved following intranasal administration of siRNAs 8, 9. As one of our goals was 
to deterrnine the effect of chemical modifications of siRNA, we opted to select two 
siRNAs targeting the hRSV P protein and two against the NS 1 protein for study. These 
siRNAs were synthesized by University Core DNA Services (University of Calgary) with 
3' dT overhangs, initially as unmodified siRNAs (Table II). 
siRNA name Sequence 
siRSV-P1 S'-CGAUAAUAUAACUGCAAGAdTdT-3' 
siRSV-P2 S'-CCCUACACCAAGUGAUAAUdTdT-3' 
siRSV-NS1 S'-GGCAGCAAUUCAUUGAGUAdTdT-3' 
siRSV-NS1a S'-GUGUGCCCUGAUAACAAUAdTdT-3' 
siRSV-P1-Mi S'-CGAUAAUACGACUGAAAUGdTdT-3' 
siRSV-P2-Mi S'-CCCUACACCGAGUAAUAUAdT dT -3' 
siRSV-NS1-Mi S'-GGCAGCAAAUCAUAUAGGUdTdT -3' 
siRSV-NS1a-Mi S'-GUGUGCCCGUAUACAAAAUdTdT -3' 
Table II. SiRNA name and sequences, siRSV-PI and siRSV-P2 were designed and tested by Bitko et al 
against the hRSV P protein 8 (shaded in yellow). The siRNA sequences were based on actual sequencing of 
the viral strains in tbeir laboratory. SiRSV-NSI and siRSV-NSla were designed according to the sequences 
by Zhang et al. to target hRSV NSI protein9(shaded in green). Mismatches (-Mi) were created with 
scrambling at various positions along the sequence. Sequences were purchased from University Core DNA 
Services from University of Calgary. 
-----------------------
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5.2.2 In vitro screening of aH four siRNAs: 
With the infection and readout methods optimized, the four unmodified siRNAs (Table 
Il, shaded in yellow and green) were screened for in vitro efficacy to inhibit RSV 
propagation~ SiRSV-Pl, -P2, -NSI and -NSla were transfected in A549cells followed _ 
by an hRSV infection 24-hours later at an MOI of 1. Supematant and ceIl lysates were 
harvested on different days post-infection according their respective readout methods. 
(A) Controls 
(B) Transfection with siRSV-P1 
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{Cl Transfection with siRSV-P2 
(D) Transfection with siRSV-NS1 
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, , 
, ' (E) Transfection withsiRSV-NS1a 
Figure 10. Inhibition of hRSV titer by immunostaining plaque assay. A549 ce lis were transfected with 
siRSV-PI, -P2, -NSI, -NSla and their respective mismatches at OA !-tg with Lipofectamine 2000 at a ratio 
of 1 :3, in duplicates, followed by an ovemight incubation at 37°C, 5%C02. Cells were then infected with 
hRSV at MOI of 1 and allowed to incubate for 2 more days in which seriai dilutions of the supematant was 
overlayed on HEp-2 cells. Immunostaining was performed on day 4 post-infection. (A) Negative and 
positive controls, (8) siRSV-PI and -Mi, (C) siRSV-P2 and -Mi, (D) siRSV-NSI and -Mi and (E) siRSV-
NS 1 a and -Mi. Plates performed in duplicate. hRSV titer was determined with the 10-3 dilution (outlined in 
. red). 
Immunostaining plaque assay was perfonned in order to obtain a precise detennination of 
the inhibition of viralload in hRSV -infected cells by any of the four siRNAs, despite the 
time-consumption involved with this assay. As controls, A549 cells were mock 
transfected followed byeither infection with hRSV or mock infection with vehic1e. 
SiRSV-PI, siRSV-P2, siRSV-NSl and siRSV-NSla were individually transfectedover 
an overlay of A549 cells followed by' an infection with hRSV at MOI of 1 24 hours 
following transfection. Cell supematant were harvested on day 2 post-infection, 
dispensed over HEp-2 cells overlayed with agar and immunostained 4 days post-
infection. Titer was only detennined for dilutions with a good number of discrete 
countable plaques. Ideally, the number of plaques per well should be between 20 and 80 
for a I2-well plate to establish the virus titer. Thus the 10-3 dilution was used for plaque 
counting (Figure 10). Two siRNAs, siRSV-P2 and siRSV-NSI appeared to have almost 
completely inhibited viral growth (90%) compared to their respective mismatches, while 
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siRSV-Pl had very mild inhibitory effect of 13% and siRSV-NSla did not appear to 
inhibit the virus whatsoever. 
Efficacy of siRSV-Pl, siRSV-P2, siRSV-NSl and siRSV-NSla to inhibit RSV infection 
of A549 cells was also assessed by determining hRSV protein levels (Figure 11), and 
secretion of MIP-Ia (Figure 12) and IL-8 (Figure 13) by these cells. When measuring 
hRSV proteins, siRSV-Pl, siRSV-P2 and also siRSV-NSla inhibited at either aIl or sorne 
doses, however siRSV-P2 was the sole siRNA among the four siRNAs that exhibited a 
non-significant dose-response inhibition (Figure 20). At the lowest 0.1 flg dose a 35% ± 
1 % inhibition was observed which increased to 55% ± 3% at the highest dose of 0.4 flg. 
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Figure 11. % Inhibition of hRSV protein in hRSV infected A549 cells. A549 cells were transfected with 
0.1 r..tg, 0.2 r..tg, and 0.4 r..tg ofsiRSV-PI, siRSV-P2, siRSV-NSI, siRSV-NSla and their mismatches with 
Lipofectamine2000 transfection reagent ratio "1 :3" in quadruplicates. A set of untransfected cell cultures 
was used as control group. One day post-transfection, cells were then infected with hRSV at MOI of 1 and 
kept incubated at 37°C, 5%COz ovemight. Supematants were harvested 24-hrs post-infection and hRSV 
protein levels were assessed by hRSV ELISA, expressed as mean ± SEM. 
Two siRNAs, siRSV-P2 and siRSV-NSl inhibited MIP-la levels (Figure 12), however 
the efficacy of siRSV-P2 was maintained throughout aIl three doses tested. Significant 
inhibitions for siRSV-P2 ranged from 48% ± 1% at the lowest dose to 58% to 73% at the 
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highest dose. Whereas for siRSV -NS l, only at the high dose of 0.4 ~g was there an 
inhibitory effect of 40%. 
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Figure 12. % lnhibition of MlP-la levels in hRSV infected A549 cells. A549 cells were transfected 
with 0.1 !J.g, 0.2 !J.g , and OA!J.g of siRSV-PI, siRSV-P2, siRSV-NSI, siRSV-NSla and their mismatches 
with Lipofectamine2000 transfection reagent ratio "1 :3" in quadruplicates. A set of untransfected cell 
cultures was used as control group. One day post-transfection, ce Ils were then infected with hRSV at MOI 
of 1 and kept incubated at 37°C, 5%C02 ovemight. Supematants were harvested 24-hrs post-infection and 
MIP-Ia levels secreted were determined by MIP-la ELISA . Data expressed as mean :t SEM . Asterisks 
indicate significant inhibition (P < 0.05). 
IL-8 secretions were inhibited solely by siRSV -P2 while the other three siRNAs appeared 
to stimulate viral production of IL-8 (Figure 13). Inhibition was observed in a dose-
dependent fashion, with a 21 % ± 5% significant inhibition at 0 .2~g and a 40% ± 9% 
inhibition at 0.4 ~g. 
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Figure 13. % Inhibition of IL-8 in hRSV infected A549 cells. A549 cells were transfected with 0.1 !-tg, 
0.2 !-tg, and 0.4 !-tg of siRSV-PI, siRSV~P2, siRSV-NSI, siRSV-NSla and their mismatches with 
Lipofectamine2000 transfection reagent ratio" 1:3" in quadruplicates. A set of untransfected cell cultures 
was used as control group. One day post-transfection, cells were then infected with hRSV at MOI of 1 and 
kept incubated at 37°C, 5%C02 ovemight. Supematants were harvested 24-hrs post-infection and secreted 
IL-8 levels were assessed by IL-8 ELISA, expressed as mean :!: SEM. Asterisks indicate significant 
inhibition (P < 0.05). 
When assessmg the results from aIl three readouts in conjunction, the siRSV-P2 
consistently demonstrated inhibition (when compared to its mismatch), whereas the other 
three siRNAs were less consistent in their efficacy as they either stimulated or inhibited 
very weakly. In aIl the readouts, a dose-dependent inhibition appeared for the siRSV -P2. 
These iesults, in addition to the evidence obtained from the immunostaining plaque 
assay, indicated that siRSV-P2 was our most promising candidate siRNA for further 
examination. 
5.2.3 In vitro screening ofsiRSV-Pl and -P2: 
Among the four siRNAs, siRSV-NSl and -NS la did not seem to have a consistent 
inhibitory effect thus we focused on an examination of the efficacy of transfection of 
siRNAs targeting the hRSV P protein. A549 cells were transfected with siRSV -P 1 and 
siRSV -P2 at a range of doses starting as low as 0.05 !Ag, followed by an hRSV infection 
the following day. Cell lysates and supematants were harvested for viral P mRNA and 
viral protein assessment, respectively. As expected siRSV-P2 proved to be the most 
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effective siRNA at attaining target knock down of the hRSV P mRNA (Figure 14). In 
this study, a low dose of 0.05 !!g was incIuded to observe a possible inhibitory effect. 
Surprisingly, at such low dose, a 42% ± 4% inhibition was observed. At the high dose of 
0.4 !!g, 89% ~ 1 % of the viral P mRNA has been effectively inhibited. These findings 
were supported by the results from the hRSV ELISA (Figure 15). 
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Figure 14_ % Inhibition of hRSV P mRNA in hRSV infected A549 cells_ A549 cells were transfected 
with 0.05 I-!g, 0.1 I-!g, 0.2 I-!g, and 004 I-!g of siRSV -P l, siRSV -P2, and their mismatches with 
Lipofectamine2000 transfection reagent ratio" 1:3" in duplicates. A set of untransfected ce1J cultures was 
used as control group. One day post-transfection, ceUs were then infected with hRSV at MOI of 1 and kept 
incubated at 37°C, 5%C02 ovemight. Cell Iysates were harvested 24-hrs post-infection for RNA extraction 
followed by reverse transcription to be assayed by real-time RT-PCR. Data was nonnalized over the Ppibg 
housekeeping gene. % Inhibition was detennined in comparison to each mismatch, respectively and 
expressed as mean ± SEM. 
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Figure 15. % Inhibition of hRSV pro teins in hRSV infected A549 cells. A549 ceUs were transfected 
with 0.05 I-!g, 0.1 I-!g, 0.2 I-!g, and 004 !-tg of siRSV -P l, siRSV -P2, and their mis matches with 
Lipofectamine2000 transfection reagent ratio" 1:3" in duplicates. A set of untransfected cell cultures was 
used as control group. One day post-transfection, ceUs were then infected with hRSV at MOI of 1 and kept 
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incubated at 37°C, 5%C02 ovemight. Supematants were harvested 24-hrs post-infection to be assessed by 
hRSV ELISA. % Inhibition was deterrnined in comparison to each mismatch, respectively and expressed as 
mean:t SEM. 
As shown in Figure 15, siRSV-P2 inhibited viral proteins in a dose-dependent manner. 
Even at the lowest dose of 0.05 !-tg a slight 4% inhibition was observed, however with an 
SEM of 13% these data cannot be of any real significance (Figure 15). Nevertheless, at 
the highest dose, 68% ofhRSV proteins were been inhibited. 
Therefore, comparing these siRNAs, it was clearly visible that siRSV-P2 consistently 
inhibited viral propagation in a dose-dependent fashion. 
5.2.4 In vitro screening of siRSV-P2 and aU its F-ANA combinations: 
In order to improve the stability and duration of activity of our siRNAs both in vitro and 
also in vivo, chemical modifications have been selected to overcome those hurdles. With 
siRSV-P2 being the most efficient at inhibiting viral growth in ail aspects, we decided to 
either completely replace the sense strand with F-ANA or only modify the two positions 
c10sest to the 3' end in the antisense strand (Table Ill), as demonstrated previously in 
vitro efficacy work done by Dowler et altO. F-ANA modifications were synthesized from 
University Core DNA Services (University of Calgary). 
siF-ANA name Sequence 
siRSV-P2 F3 5'-CCCTACACCAAGTGAT AA TTT-3' 
siRSV-P2 F4 5'-AUUAUCACUUGGUGUAGGGTT-3' 
siRSV-P2-Mi F3 5' -CCCTACACCGAGT AA TATA TT-3' 
siRSV-P2-Mi F4 5'-UAUAUUACUCGGUGUAGGGTT-3' 
Table III. F-ANA modified siRNA names and sequences. F-ANA modifications were made for siRSV-
P2 at various positions along the siRNA strands (shaded in yellow), denoted in bold. Mismatches (-Mi) 
were created with scrambling at various positions along the sequence. Sequences were purchased from 
University Core DNA Services from University of Calgary. 
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Cell lysates and supernatants from siRNA-transfected hRSV-infected A549 cells were 
harvested for evaluation for inhibition of hRSV replication. AIl siRNAs, unmodified and 
F-ANA modified, appeared to inhibit viral P mRNA at doses higher than 0.1 !-tg (Figure 
16). At the lowest dose of 0.05 !-tg, only siRSV-P2 F3/F4 10st its inhibitory effects. 
Interestingly, siRSV -P2 0/F4 inhibited 30% better than the unmodified siRNA at the 
lower doses while maintaining a similar inhibitory effect of approximately 92% at the 
highest dose. 
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Figure 16. % Inhibition of hRSV P rnRNA in hRSV infeded A549 cells. A549 cells were transfected 
with 0.05 ~g, 0.1 ~g, 0.2 ~g, and OA ~g siRSV -P2 0/0, 01F4, F3/0 F31F4, and their mismatches with 
Lipofectamine2000 transfection reagent ratio "1 :3" in duplicates. A set of untransfected cell cultures was 
used as control group. One day post-transfection, cells were then infected with hRSV at MOI of 1 and kept 
incubated at 37°C, 5%C02 ovemight. Celllysates were harvested 24-hrs post-infection for RNA extraction 
followed by reverse transcription to be assayed by real-time RT-PCR. Data was normalized over the Ppib 
housekeeping gene. % Inhibition was determined in comparison to each mismatch, respectively and 
expressed as mean ± SEM. 
Inhibition of hRSV proteins however did not parallei the inhibition of viral P mRNA 
(Figure 17). Using this readout, siRSV -P2 % and 0/F4 were still inhibitory as well as 
the F3/F4 modification, consistent with the findings by Dowler, where increased potency 
was observed when modifications at the 3' -end were made, with minor loss when the 
entire sense strand was converted in addition 10. Unmodified siRSV -P2 appeared to 
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inhibit 38.8% greater than the 0/F4 at 0.1 !Ag with an 85% ± 1 % inhibition, however 
efficacy of the unmodified siRNA quickly decreased at 0.05 !Ag dose. At this low dose, 
both % and 01F4 inhibit at similar levels however 0/F4 with a slight increment of an 
advantage, whereas F3/0 was not inhibitory. 
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Figure 17. % Inhibition of hRSV proteins in hRSV infected A549 cells. A549 cells were transfected 
with 0.05 flg, 0.1 flg, 0.2 flg, and OA flg of siRSV-P2 0/0, 01F4, F3/0, F31F4 and their mismatches with 
Lipofectamine2000 transfection reagent ratio" 1 :3" in quadruplicates. A set of untransfected cell cultures 
was used as control group. One day post-transfection, cells were then infected with hRSV at MOI of 1 and 
kept incubated at 37°C, 5%C02 overnight. Supernatants were harvested 24-hrs post-infection to be assessed 
by hRSV ELISA. % Inhibition was determined in comparison to each mismatch, respectively and 
expressed as mean ::!: SEM. 
Inhibition of MIP-Ia secretion by the hRSV-infected A549 cells with siRSV-P2 0/0, 
0/F4, F3/0 and F3/F4 is summarized in Figure 18. There is a distinct segregation 
between the siRNAs that inhibited cytokine secretion as compared to those that had 
stimulatory effects. SiRSV -P2 F3/0 and F31F4 clearly did not inhibit the MIP-I a levels 
whatsoever, while both % and 0/F4 inhibited at almost the same levels. Unmodified 
siRSV-P2 at the highest dose (0.4 )lg) managed to almost completely inhibit MIP-I a 
secretions by 96%. 
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Figure 18. % Inhibition of MIP-Ia in hRSV infected A549 cells. A549 cells were transfected with 0.1 
""g, 0.2 ""g, and 0.4 ""g ofsiRSV-P2 010, 0/F4, F3/0, F31F4 and their mismatches with Lipofectamine2000 
transfection reagent ratio" 1 :3" in triplicates. A set of untransfected cell cultures was used as control group. 
One day post-transfection, cells were then infected with hRSV at M.O.! of 1 and kept incubated at 37°C, 
5%C02 ovemight. Supematants were harvested 24-hrs post-infection and MIP-Ia levels secreted were 
determined by MIP- 1 a ELISA. % Inhibition was determined in comparison to each mismatch, respectively 
and expressed as mean :!: SEM. 
When examining al! three readouts together, a pattern emerges. Unmodified siRSV -P2 is 
indeed the best choice of siRNA amongst the initial four siRNA as it reliably inhibited 
viral replication as determined in al! readouts. F-ANA modifications of siRSV -P2 F3/0 
and F31F4 did not appear to have much inhibitory effect while 0/F4 looked promising as 
it demonstrated better efficacy at inhibiting target mRNA than the unmodified siRSV -P2 
at lower doses, although inhibited levels of viral proteins and MIP-I a similar to the 
unmodified version. Our next step was to determine the efficacy of these siRNAs in an 
animal model of hRSV infection. 
5.3 V ALIDA TION OF IN VIVO MODEL. 
As the results from our in vitro studies suggested that the siRNAs, siRSV-P2 % and 
0/F4 exhibited the greatest efficacy in reducing levels of RSV replication we next 
explored the efficacy of these two siRNAs in an animal model of hRSV infection. 
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Humans are the natural host for hRSV and an exact representation of the disease cannot 
be identically reproduced in any other species, however efficient hRSV replication has 
been shown to take place in BALB/c mice 297. We first had to assess the course and 
robustness of the infection in BALB/c mice using the hRSV inoculum we prepared in 
house. 
5.3.1 Developing an in vivo mou se hRSV modeI. 
To determine the optimal viral load in the hRSV murine model, mice were infected with 
both a high and low titer of hRSV preparations. Preliminary studies were performed by 
infecting BALB/c mice with a single dose of hRSV delivered intranasally (in 50 fAI) and 
physiological symptoms were monitored daily. Viral load and immune response were 
assessed on days 3, 6 and 10 post-infection (Figure 19). 
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Figure 19. Timeline of hRSV infection. BALB/c mice were anesthetized with a mixture of ketamine-
xylazine then infected with 50 f.tL of vehicle, UV -irradiated hRSV at 1 x 1 06 PFU, and active hRSV at 1 x 105 
PFU or 1 x 1 06 PFU by nasal instillations. On days 3, 6, and 10 following infection, 5 mice from each group 
were weighed, anesthetized with an overdose of sodium pentobarbital and exsanguinated. BALs and whole 
lungs were collected from the mice on those days post-infection. 
Following infection, upon external examination the mice exhibited no visible cold-like 
symptoms or signs of distress (i.e. fur ruffling, huddling, lack of activity). However 
variations in weight gain were detected between the treatment groups (Figure 20). 
Animais in the control group (mock infected with vehicle) appeared to steadily gain 
weight as the days progressed, always weighing heavier compared to animais in the other 
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groups and did not appear to have an initial drop in weight observed with all other 
treatments. Mice infected with the highest dose of virus (1 x 1 06 PFU) always weighed the 
least compared to the other treatment groups (either mock-infected, UV-tn~ated hRSV 
and low titer hRSV groups), with an initial drop in weight on day 2 post infection: 
Nevertheless even this group of mice showed steady weight gain aft~r the initial weight 
drop. Mice infected with the lower dose of hRSV (1 x 1 05 PFU) also had an initial drop in 
weight as measured on Day 2 post infection, but by the end of the time course animaIs in 
this group were approaching weight gains similar to control animaIs suggesting that the 
low titer of virus was not bringing long term physiological changes to the mice. 
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Figure 20. Mouse weight difference in percentage measured over time. BALB/c mice were weighed on 
ay 0, 3, 7 and 10 post-infection. Percent weight differences of the mean of each group were calculated 
compared to the starting weight at day ° post-infection (± SEM). 
Mice were sacrificed on days 3, 6 and 10 post-infection for BAL and whole lung 
collection. Total and differential cells were determined from BAL (Figure 21, 22 and 
23). On day 3 post treatment, animaIs from all groups demonstrated a consistent elevation 
in total number of cells in BAL regardless of whether they were infected with the virus or 
not suggesting that there is a rapid influx of cells to the lungs following intranasal 
administration (Figure 21). The total number of BAL cells in both control groups, 
vehicle only and UV -irradiated hRSV, decreased gradually by day 10 indicating that the 
immune system was no longer activated. Mice infected with either the low or high titer 
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virus did not demonstrate this drop in cell numbers over time and instead appeared to 
maintain or have an increase in total cells in BAL, suggesting that these animais were to 
efficiently infected with the virus. The drop in the total number of cells observed on day 
6 might in ail treatrnent groups reflect the regress of cells, which were called into the lung 
in response to a non-specifie assault of nasal instillation. The maintenance of the elevated 
cell numbers by day 10 in the RSV infected animais (see figure 21) suggest that these 
animais are expressing an immune response to the virus, specifically from the 
lymphocytes (Figure 22 and 23). 
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Figure 21. Total cells in BAL of hRSV infected BALB/c mi ce over time. Mice were sacrificed on either 
day 3, 6 or JO post-infection. BALs were then perfonned by injecting and retrieving 5 times 0.8 mL of cold 
PBS into the lungs. Total cell count was detennined for each sample and expressed as me an ± SEM per 
group (n=5 mice per group). 
Differentiai cells counts (percent and absolute cell numbers) were also performed on the 
BAL (Figure 22 and 23). Mice in either vehic1e treated group or UV -treated RSV groups 
demonstrated similar profiles in cell sub-populations present in the BAL over time. 
Macrophages made up the largest percentage of infiltrating cells in animaIs of these 
groups at ail time pOints. In contrast, animais infected with viable hRSV demonstrated an 
initial high level of macrophages on Day 3, which decreased over the time course. 
Instead the levels of lymphocytes in these animaIs increased by Day 6 and Day 10. 
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FÏ!:ure 22. Percent differential cells in BAL of hRSV infected mice over time. Mice were sacrificed on 
either day 3, 6 or 10 post-infection. BALs were then performed by injecting and retrieving 5 times 0.8 mL 
of cold PBS into the lungs. Total cell counts were determined for each sample and then differential cell 
counts were prepared on slides using cytospins. Slides were stained with the Hema 3 stain set. Percent 
differential cell count was determined for each sample expressed as mean ± SEM per group (n=5). 
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Figure 23. Absolute number of differential cells in BAL of hRSV infected mice over time. Mice were 
sacrificed on either day 3, 6 or 10 post-infection. BALs were then performed by injecting and retrieving 5 
times 0.8 mL of cold PBS into the lungs. Absolute cell counts was determined for each sample expressed as 
mean ± SEM per group (n=5). 
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Besides determining the total and differential cell counts in BAL, we also measured BAL 
for levels of hRSV (using hRSV ELISA and real-time PCR), as weIl as cytokines, mMIG 
(mouse monokine induced by IFN-gamma) and TNF-alpha, as a marker of immune cell 
activation. Both MlG and TNF-a have been previously linked to persistent airway 
inflammation, due to continuous chemotaxis of mononuclear cells 298 299 8 and also to 
RSV disease severity 300, respectively in BALB/c mice. In mice treated with the highest 
titer of hRSV Jevels of viral infection (hRSV proteins) were observed on Day 3 and Day 
6 post infection, with clearance by Day 10. Mice infected with lower titer of virus had 
modest levels of hRSV proteins in BAL on Day 3 and Day 6 post infection and also 
cleared by Day 10 (Figure 24). Real-time RT-PCR results indicated that hRSV P mRNA 
could be identified on both day 3 and 6 with both RSV infected groups (high and low 
titer), however with a stronger dose-dependent signal at the peak of infection on day 6 
(Figure 24 B). With regard to cytokines, MIG levels were highest on Day 6 post 
infection in both high and low titer infected animais with clearance of MIG by Day 10 
post infection. In contrast, TNF-a was only detectable on day 3 post-infection for aIl 
animal groups and was highest in the group infected with the highest titer of RSV. A 
consistent pattern in hRSV protein, viral P mRNA and mMIG levels appears throughout, 
in which a peak in viral replication is observed 6 days foIlowing infection and becoming 
undetectable by day 10. 
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Figure 24. Determining hRSV infection in BAL and lung homogenates of hRSV infected BALB/c 
mi ce over time. BALB/c mice were infected by nasal installation with vehicle, UV-irradiated hRSV at 
1 x 106 PFU , active hRS V at 1 xl 05 PFU or 1 x 1 06 PFU in 50 !AL in one nostril. Animais were sacrificed at 
time points post infection and BAL fluids were collected and analyzed by (A) hRSV protein ELISA, (C) 
mouse MIG ELISA, and (D) TNF-alpha ELISA assays. Whole lungs were collected after BALs were 
perforrned and real time PCR was perforrned (B) on RNA isolated from the lung homogenates . cDNA was 
made with Random Hexamers by reverse transcription and then quantitated by real-time PCR using viral 
RSV-P primers. ~2M was the housekeeping gene used as reference. Samples expressed as mean ± SEM per 
group (n=5 mice per group) . 
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5.3.2 Optimizing the in vivo mouse hRSV model 
Due to the abundant number of mice used and the lengthy amount of time for each set of 
experiments a single optimal dose and single harvest day would be highly favorable to 
conduct efficacy testing of our selected siRNAs. We had previously deterrnined that both 
low and high titer of hRSV were sufficient to infect the mice and elicit an immune 
response, however the lower titer of 1 xl 05 PFU was barely detectable by hRSV protein 
ELISA while infections with 1 x 1 06 PFU would require an great amount of virus. We 
therefore tested a median dose of 5 xl 05 PFU per mouse and included an additional 
harvest on Day 1 post-infection to further optimize this model of hRSV infection in the 
BALB/c mice. 
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Fil.!:ure 25. Timeline of hRSV infection. BALB/c mice were anesthetized with a mixture of ketamine-
xylazine th en infected with either 50 flL of vehicle or active hRSV at 5x 1 05 PFU by nasal instillations. On 
days 1,3,6, and 10 following infection, 5 mice from each group were weighed, sacrificed and BALs and 
whole lungs were collected. 
On Day 1 post infection, BAL from animais in both treatment groups demonstrated 
increased numbers of total cells (Figure 26). In animais infected with hRSV (5x105 
P.F. U), again there was an increase in total cells in BAL on Day 6 and Day 10 post 
infection while in control animais total cell numbers appeared to plateau. For both 
treatment groups, between 40-50% of the cells present at Day 1 were neutrophils (Figure 
27) and these levels feU by Day 3 suggesting that this early influx of cells into the lungs 
may be a non-specific response to nasal instillation rather than a specific immune 
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response to virus, although in the case of RSV infection, neutrophils have been shown to 
be the early responders 30 l, 302. 
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Figure 26. Total cells in BAL of hRSV infected BALB/c mice over time. Mice were sacrificed on either 
day 1, 3, 6 or 10 post-infection. BALs were perforrned and total cel! counts were deterrnined for each 
sample and then averaged per group (n=5 mice per group) ± SEM. 
Similar to what was previously observed with high and low titer infections, the medial 
inoculum of 5x 1 05 PFU per mouse of virus led to an increase in lymphocytes over the 
time course of infection (Figure 27 and 28) as weil as an increase in the absolute number 
of macrophages (Figure 28). 
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Figure 27. Percent differential cells in BAL of hRSV infected mice over time. Mice were sacrifice on 
either day l, 3, 6 or 10 post-infection. BALs were then perforrned and total cell counts deterrnined. Cel! 
concentrations were then adjusted to 1 x 1 06 cells/mL and cytospins were prepared on glass slides. Slides 
were stained with the Hema 3 stain set. Percent differential cell count was deterrnined for each sample 
expressed as mean ± SEM per group (n=5). 
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Figure 28. Absolute number of differential cells in BAL of hRSV infected mice over time. Mice were 
sacrificed on either day l, 3, 6 or la post-infection. BALs were perforrned, differential perforrned and 
absolute cell count was determined for each sample, expressed as mean ± SEM per group (n=5). 
Again to further characterize the infection model in response to 5xl05 PFU we measured 
levels of hRSV prote in, mRNA and murine cytokines MIO and TNF-a (Figure 29) in the 
BAL. hRSV proteins and mRNA were detected as early as the next day following 
infection, increased on Day 3, peaked on day 6 (Figure 29 A and B) and fell by Day 10, 
similar to the pattern observed with low and high titer infections (Figure 24). With 
regard to cytokines, only the hRSV-infected group of mice exhibited levels of MIO and 
only on day 6 post-infection, whereas TNF-a was detectable immediately after nasal 
instillation on Day 1 in both treatment groups (Figure 24 C and D). Taken together, 
these results suggested that a Day 6 post-infection time point would be an optimal harvest 
day to assess viral infection. 
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Figure 29. Determining hRSV infection in BAL and lung homogenates of hRSV infected BALBtc 
mi ce over time. BALBtc mice were infected by nasal installation with vehic1e or active hRSV at 5x 1 OS 
PFU in 50 ~L in one nostril. Animais were sacrificed at indicated times post infection and BAL fluids were 
collected and analyzed by (A) hRSV protein ELISA, (C) mouse MIO ELISA, and (0) TNF-alpha ELISA 
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assays. Whole lungs were collected after BALs were collected and real-time PCR performed on (8) RNA 
isolated from the lung homogenates. cDNA was made with Random Hexamers by reverse transcription and 
then quantitated by real-time PCR using viral RSV-P primers. ~2M was the housekeeping gene used as 
reference. Samples expressed as mean:!: SEM per group (n=5 mice per group). 
5.3.3 Validation of murine hRSV mode) via treatment with ribavirin 
As our previous results indicated an optimal viral dose of our hRSV to be 5x 1 05 PFU per 
mou se for our model, we felt it was important to further validate this optimized animal 
model by attempting to reduce the infection with the CUITent treatrnent available on the 
market, ribavirin. To this end, 5x 1 05 PFU of hRSV was na sally instilled into mice 
followed by subcutaneous injections of ribavirin daily (low and high doses) until peak of 
infection where they were sacrificed to assess viral load and immunological responses 
(Figure 30). 
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Figure 30. Timeline of hRSV infection. BALB/c mice were anesthetized with a mixture of ketamine-
xylazine then iufected with 50 ilL of vehicle or active hRSV at 5x 105 PFU by nasal instillations. In addition 
to being infected, mice were then either given a low (50 mglkglday) or high (500 mglkg/day) dose of 
ribavirin subcutaneously daily. Day 6 folJowing infection, 5 mice from each group sacrificed, and BALs 
and who le lungs were collected for further analyses. 
The c1inically relevant dose of ribavirin calculated for the murine model was determined 
to be 50 mg/kg/day. In order to exaggerate any inhibitory effect of treatment, an extreme 
dose of 500 mg/kg/day was also inc1uded in this study. Results of total cell numbers in 
BAL of treated mice demonstrate no effect of the 50-mg/klday dose of ribavirin to reduce 
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cellular infiltrate whereas 500-mg/kg/day ribavirin dose demonstrated a mode st inhibition 
of 8.5% (Figure 31). 
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Figure 31. Total cells in BAL of hRSV infected BALB/c mice over time. Mice were sacrificed on day 6 
post-infection. BALs were performed and total cell counts determined. Data expressed as mean ± SEM per 
group (n= 5 mice per group). 
Ribavirin treatment did significantly inhibit the increase in lymphocytes by almost half 
the amount with just 50 mglkg/day (see % Iymph, bar 3 in Figure 32 and 33), and a 
similar effect with the high dose ofribavirin (refer to bar 4 in % Iymph). 
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Figure 32. Percent differential cells in BAL of hRSV infected mi ce over time. Mice were sacrificed on 
day 6 post-infection. BALs were performed and total oeil counts were determined for each sample. Cell 
concentrations were th en adjusted to 1 xl 06 cells/mL and cytospins were prepared on glass slides. Slides 
were stained with the Hema 3 stain set. Percent differential cell count was determined for each sample 
expressed as mean :t SEM per group (n=5). Asterisks indicate significant inhibition (P < 0.05). 
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Figure 33. Absolute number of differential cells in BAL of hRSV infected mice over time. Mice were 
sacrificed on day 6 post-infection. BALs were perforrned and absolute cell counts deterrnined. Data 
expressed as mean ± SEM per group (n= 5 mice per group). 
Treatment of mice with ribavirin was also able to inhibit both viral protein and mRNA 
levels, with the greatest efficacy observed with the high dose ribavirin, which 
significantly inhibited protein levels by 53% (Figure 34 A) and viral P mRNA levels by 
33%, (Figure 34 B). As animais were sacrificed on Day 6 post infection we opted to 
measure mouse MIG levels only as an indication of immune cell activation. Ribavirin 
(high dose) treated significantly abrogated mouse MIG induction by 97% (Figure 34 C). 
Although these levels of inhibition are impressive, 500 mg/kg/day exceeds the 
recommended dose by 10 times, while the modest effect of the 50 mg/kg/day dose would 
be more representative of a clinical response to this therapy. The use of ribavirin as a 
method of validating the hRSV mouse model was effective. The inhibition observed with 
the high dose also validated the infection dose of 5xl05 PFU per mouse, the day 6 post-
infection harvesting time-point and the readout methods. 
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Figure 34. Determining hRSV infection in BAL and lung homogenates of hRSV infected BALB/c 
mice over time.BALB/c mice were infected by nasal instillation with vehicle or active hRSV at 5xlOs 
PFU in 50 !AL in one nostril, and injected daily with ribavirin subcutaneously at 50mg/kg/day or 
500mg/kg/day. BAL fluids were collected and analyzed by (A) hRSV protein ELISA and (C) mouse MIO 
ELISA assays. Whole lungs were collected after BALs were perfonned. (B) RNA was isolated from the 
lung homogenates. cDNA was made with Random Hexamers by reverse transcription and then quantitated 
by real-time PCR using viral RSV-P primers. j32M was the housekeeping gene used as reference. Samples 
expressed as mean SEM per group (n=5 mice per group). Asterisks indicate significant inhibition (P < 
0.05). 
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5.4 DETERMINATION OF EFFICACY OF siRNA IN AN ANIMAL MODEL OF 
hRSV INFECTION: 
5.4.1 Determination of ln vivo efficacy of unmodified siRSV-P2, preliminary 
experiments 
The optimized infection model thus far required for the nasal instillation of hRSV at 
5x 1 05 PFU per mouse with harvesting of BAL and lungs 6 days post-infection. With the 
model set up and vatidated, we set out to assess the efficacy of the best siRNA sequences 
selected from in vitro studies. 
Two doses of unmodified siRSV-P2 (also denoted as siRSV-P2 010) was administered 
intranasally in 50 !-lL volume (naked in PBS) followed by an infection with 5x 105 PFU 
into the same nostril. BAL and whole lungs were collected 6 days later for assessment of 
viral load and immunological reactions (Figure 35). The following data shows a 
representative experiment of the efficacy screening of siRSV -P2 010. 
hRSV siRNA 
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Figure 35. Timeline of hRSV infection. BALB/c mice were anesthetized with a mixture of ketamine-
xylazine then infected with 50 ~L of vehicle or active hRSV at 5x 105 PFU by nasal installations. Following 
infection, 50 ~L of naked 25 ~g or 50 ~g siRSV-P2 0 10 was administered intranasally. 6 days post-
infection , BALs and who le lungs were collected from 5 mice per treatment group. 
Upon analysis of the cellular infiltrate into the lungs on Day 6 post-infection, in this 
experiment the level of total cells in the hRSV-infected group was similar to levels 
observed in the vehicle control group (Figure 36) mainly linked to the surge of 
neutrophils and decrease in macrophages in the hRSV -infected group (data not shown) 
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consistent with results previously seen. Treatment of animaIs with either dose of siRSV-
P2 resulted in a non-significant stimulation instead of inhibition of total cells when 
compared to either the hRSV only control group or their respective mismatches. 
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Figure 36. Total cells in BAL of hRSV infected BALB/c mice over time. Mice were sacrificed on day 6 
post-infection. BALs were performed by injecting and retrieving 5 times 0.8mL of cold PBS into the lungs. 
Total cell count was determined for each sample and expressed as mean ± SEM per group (n=5). 
Although no decrease in total cell numbers was observed in response to siRSV-P2 
treatment, there was a modest inhibition of percent of lymphocytes in BAL when hRSV-
infected mice were treated with siRSV-P2 % (Figure 37). At both the 25 !-tg and 50 !-tg 
doses, the increase in lymphocytes was impeded by 15% and 12%, respectively, 
compared to the control hRSV only group (non-significant). Only a 6% inhibition of the 
absolute number of cells was detectable with the lower dose of siRSV-P2 (Figure 38). 
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Figure 37. Percent lymphocytes in BAL of hRSV infected mice over time. Mice were sacrificed on day 
6 post-infection. BALs were then performed by injecting and retrieving 5 times 0.8 mL of cold PBS into 
the lungs. Total cell cou nt was determined for each sample. Cell concentrations were then adjusted ta 1 x 106 
cells/mL and cytospins for differential cell counts were prepared on glass slides. Slides were stained with 
the Hema 3 stain set. Percent differential cell count performed and the percent lymphocytes for each sample 
was expressed as mean ± SEM per group (n=5). 
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Figure 38. Absolute number of lymphocytes in BAL of hRSV infected mice over time. Mice were 
sacrificed on day 6 post-infection. BALs were then performed by injecting and retrieving 5 times 0.8 mL of 
cold PBS into the lungs. Absolute number of lymphocytes was determined for each sample, expressed as 
mean ± SEM per group (n=5). 
Looking at levels of RSV proteins in the BAL of these animaIs it was observed that 
unmodified siRSV-P2 at 25 !-tg and 50 !-tg per mouse inhibited the levels of hRSV 
proteins by 17% and 24% respectively (Figure 39 A, bar 3 and 5). The effect of 
mismatch siRNA sequences were often inconsistent and appeared to have inhibitory 
effects therefore for in vivo evaluations of aIl data, aIl inhibitions were compared to the 
hRSV-infected only control group (i.e. bar 2 in aIl three readouts of Figure 39). With 
regard to inhibition of mRNA, levels were not inhibited in response to treatment with the 
low dose of siRSV-P2 however an inhibition of 33% was observed in response to the 
higher dose treatment (Figure 39 B, bar 5). Inhibition of mouse MIG levels was observed 
with low dose siRSV-P2 to be 17% and 36% with the high dose of siRSV-P2 (50 !-tg) 
(Figure 39 C, bar 3 and 5 respectively). The results from aIl three readouts are suggestive 
of a dose-dependent inhibitory response to hRSV by the siRNA. 
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Figure 39. Determining hRSV infection in BAL and lung homogenates of hRSV infected BALB/c 
mice over time. BALB/c mice were infected by nasal installation with vehic1e or active hRSV at 5xl05 
PFU in 50 !-tL in one nostril, followed by 50 !-tL of naked 25 !-tg or 50 !-tg siRSV-P2 % administered 
intranasally. Lungs were washed 5 times with 0.8 mL of cold PBS and BAL fluids were collected and 
analyzed by (A) hRSV protein ELISA and (C) mouse MIG ELISA assays. Whole lungs were collected 
after BALs were performed. (B) RNA was isolated from the lung homogenates. cDNA was made with 
Random Hexamers by reverse transcription and then quantitated by real-time PCR using viral RSV-P 
primers. ~2M was the housekeeping gene used as reference. Samples expressed as mean ::!:: SEM per group 
(n=5 mi ce per group). 
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In view of the fact that these data are from a single experiment representative of the 
efficacy of unmodified siRSV -P2 at two doses, no concrete conclusions can be drawn 
from such results. In the fo\\owing section, aH experiments using unmodified siRSV -P2 
were pooled and compared to pooled data oftreatments with F-ANA modified siRNAs. 
5.5 COMPARISON OF IN VIVO EFFICACY OF UNMODIFIED VS. F-ANA 
MODIFIED siRNA. 
5.5.1 Comparison of in vivo efficacy of unmodified siRSV-P2 % vs. F-ANA 
modified siRSV-P2 01F4, pooled analysis 
In vitro screening of siRNAs showed promising results with siRSV -P2 % and 0/F4 and 
next we wished to assess the efficacy of the unmodified and F-ANA modified siRNA in 
our animal model of hRSV infection. Unmodified and F-ANA modified siRSV -P2 were 
intranasally administered at two doses followed by infection with hRSV at 5x 1 05 PFU 
per mouse. Viral load and immune responses were analyzed 6 days post-infection 
(Figure 40). As a control treatment, ribavirin was delivered subcutaneously to a subgroup 
of infected mice on a daily basis as described below (Figure 50). 
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Figure 40. Timeline of hRSV infection. BALB/c mice were anesthetized with a mixture of ketamine-
xylazine then infected with 50 f!L of vehicle or active hRSV at 5xlOs PFU by nasal installations. In 
addition to being infected, mi ce were then either given a low (50mg/kg/day) dose of ribavirin 
subcutaneously daily. Day 6 following infection, 5 mice from each group were weighed, anesthetized with 
an overdose of sodium pentobarbital BALs and whole lungs were collected from the mice on those days 
post-infection. 
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Results from these studies showed the failure of ribavirin and siRSV-P2 (either 
unmodified or F-ANA modified) to affect the total cell numbers present in BAL (Figure 
41). These results coincided with the slight stimulation of total cell counts observed 
previously with unmodified siRNAs at both high and low doses. Upon examination of the 
differential cell counts however, inhibitions varied from cell type to cell type (Figure 
42). hRSV infection stimulated an infiltration of percent lymphocytes and both siRSV-P2 
0/0 and siRSV -P2 01F4 successfully inhibited this lymphocyte influx at both the 25 !-tg 
and 50 !-tg doses (Figure 42 A, on the left). Unmodified siRSV-P2 demonstrated 
moderately better inhibitory effects than F -ANA modified with 18% and 20% at the low 
and high dose respectively while F-ANA modified siRSV-P2 inhibited 15% at high dose 
only. In contrast, mice treated with ribavirin had over twice the levels of inhibition, 
inhibiting percent lymphocyte levels by 47% (Figure 42 A, on the left, bar 5). With 
regard to neutrophils, ribavirin treatinent inhibited by 76% (Figure 42 C, on the left, bar 
5) and treatment with low doses of siRSV-P2 also decreased the percent neutrophils in 
the lungs by 38% for % and 41% for 01F4 (Figure 42 C, on the left, bar 1 and 3). In 
contrast to these cell types, macrophages (percent and absolute numbers) were increased 
in mice with all treatments (Figure 42 B). Similarly, both unmodified and F-ANA 
modified siRSV -P2s did not inhibit percent and absolute levels of eosinophils, whereas 
ribavirin was effective by 47% and 16%, respectively (Figure 42 D). 
25 
., -75 
-100 
25 l'U 1 50 l'U 
1IiJtSY-P2 010 
50 
rng/kl/d 
RiNvirtn 
Figure 41. % Inhibition of total cells in BAL of hRSV infected BALB/c mice over time. Mice were 
sacrificed on day 6 post-infection. BALs were then perfonned by injecting and retrieving 5 times 0.8 mL of 
cold PBS into the lungs. Total cel! count was determined for each sample and expressed as mean (n= 15-33 
mice per siRNAtreatment group, n= 17 per ribavirin group) ± SEM. 
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Figure 42. % Inhibition of cells released in BAL of hRSV infected BALB/c mice (measured by total 
and differential cell counts). Mice were sacrificed on day 6 post-infection. BALs were then performed by 
injecting and retrieving 5 times 0.8 mL of cold PBS into the lungs. Total cell count was determined for 
each sample. Cell concentrations were then adjusted to 1 x 106 cells/mL and cytospins for differential cell 
counts were prepared on glass slides. Slides were stained with the Hema 3 stain set. Percent and absolute 
cell counts were determined for each sample, expressed as mean (n=15-33 mice per siRNA treatrnent 
group, n= 17 per ribavirin group) :!: SEM. 
The efficacy of the unmodified and F-ANA modified siRSV-P2 upon RSV proteins, 
mRNA levels and cytokines in BAL were also investigated. Inhibition of hRSV viral 
proteins occur in a dose dependent manner in mice treated with both unmodified and F-
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ANA modified siRSV-P2 (Figure 43). At the low and high dose, hRSV viral proteins 
were inhibited at 31 % and 44%, respectively, by unmodified siRSV-P2. The efficacy of 
F-ANA modified siRSV-P2 inbibited viral proteins at similar levels to that ofunmodified 
siRSV -P2 at both the high and low doses, with 25% and 48%. Protein levels inhibited by 
ribavirin at 50 mglkg/day everyday were comparable to the inhibition levels observed 
with either siRSV-P2 % and 0/F4, with 50 !-tg given at a single time point immediately 
prior to infection. 
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Figure 43. % Inhibition of hRSV proteins in BAL of hRSV infected BALB/c mice (measured by 
hRSV ELISA). Animais were sacrificed on day 6 post infection and BAL fluids were collected and 
analyzed by hRSV protein ELISA. Inhibition of hRSV proteins expressed as % mean ± SEM per group 
mean (n=15-33 mice per siRNA treatment group, n=17 per ribavirin group). 
* 
ao 
c 
! 
4D 
j! 20 ~ 
C 
... ,. 0 
-20 
1 1 
25~ 5O~ 25l1li 50 110 50 
rng/kg/d 
IliRSV-P20/0 IliRSV-P20/P-4 Ribavirin 
Figure 44. % Inhibition of hRSV P mRNA levels detected in lung homogenates of hRSV infected 
BALB/c mice (measured by real-time RT-PCR). Animais were sacrificed on day 6 post infection and 
whole lungs were collected after BAL. Real-time PCR was performed and analyzed by RNA isolated from 
the lung homogenates. cDNA was made with Random Hexamers by reverse transcription and then 
quantitated by real-time PCR using viral RSV-P primers. B2M was the housekeeping gene used as 
reference. Inhibition of hRSV P mRNA expressed as mean ± SEM per group (n=15-33 mice per siRNA 
treatment group, n= 17 per ribavirin group) . Asterisks indicate significan t inhibition (P < 0.05). 
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Figure 45. % Inhibition of mouse MIG levels in BAL of hRSV infected BALB/c mice (measured by 
mMIG ELISA). Animais were sacrificed at indicated times post infection and BAL fluids were coUected 
and analyzed by mouse MIG ELISA, Inhibition of mouse MIG expressed as mean ± SEM per group 
(n=15-33 mice per siRNA treatment group, n=17 per ribavirin group). 
At the mRNA 1evel, a 37% target knockdown ofhRSV P mRNA was observed at the low 
dose with F-ANA modified siRSV-P2, which was significantly higher th an the efficacy 
of the unmodified siRSV-P2 (6%) at this same dose (Figure 44, bar 3 and l, 
respectively). This enhancement in efficacy of siRSV -P2 01F4 at the low dose is 83% 
greaterthan that of the unmodified siRSV -P2. At the high dose of 50 f,lg per mouse, both 
unmodified and F-ANA modified siRSV-P2 inhibited at similar levels, of 38% and 29%, 
suggesting that a plateau in dosage was reached. Unlike with the other readouts, 
interesting1y, ribavirin was less effective at inhibiting viral mRNA, with only a 16% 
target knockdown (Figure 45, bar 5). With regard to mouse MIO 1evels, inhibition 
achieved by siRSV-P2 010 and 01F4 were of approximately similar levels at both low 
and high doses, averaging 17%, however treatment with ribavirin was greater with an 
inhibition of 40% (Figure 45). These results in conjunction demonstrated that both 
unmodified and F-ANA modified siRSV-P2 exhibited inhibition of viral mRNA and 
proteins, both direct viral readouts, regardless of the lesser inhibition levels observed with 
the indirect mouse MIO readout. 
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Human respiratory syncytial virus is the leading cause of severe lower respiratory tract 
disease in youngchildren and an important cause of morbidity and mortality in the 
.elderly and the immunosuppressed. Despite extensive research, development of an 
effective vaccine against the virus has been difficult due to the partial immune response 
towards hRSV. Currently, the Ollly antiviral therapy available is ribavirin, however its use 
is controversial both in regards to efficacy and cost-effectiveness 6. Recent studies with 
small interfering RNAs have demonstrated inhibition of hRSV replication by targeting 
the viral P 8 and NS 1 proteins 9 in a murine model. Despite the high inhibition efficacy 
levels achieved by their siRNAs of RSV repli cation in mice, in order to become a 
potential optimized drug, critical changes must be addiessed including prolonging their 
half-lives, enhancing their stability, and increasing their affinity with RNA, safety and 
bio-distribution without compromising biological activity. We therefore investigated the 
efficacy of a chemically modified siRNA with F-ANA at inhibiting hRSV replication 
both in culture and also in a mouse model. 
After the initial set up of an in vitro hRSV infection in the A549 cell line, four siRNAs 
. were screened for their efficacies. Two siRNAs, siRSV-PI and siRSV-P2 were targeting 
, 
the viral P gene and which the other two were targeting the viral NS 1 gene. By targeting 
the genes essential in the process of hRSV replication, we expected to inhibit not only 
replication but also viralload.ln vitro results suggested that although both siRSV-P2 and 
. , 
· siRSV-NSI inhibited almost completely viral plaque growth, only siRSV-P2 
demonstrated consistent inhibition of mRNA, of viral proteins, and also cytokine levels in 
a dose-dependent manner. Up to an 89% knockdown of hRSV P mRNA and a 68% 
inhibition of viral proteins was observed with siRSV-P2 at a dose of OA fig when 
· compared to their respective control mismatches. Cytokine levels, such as MIP-I a and 
IL-8, were aiso inhibited up to 73% and 40% with siRSV-P2, respectively. SiRSV-NSl 
t, 
on the other hand, demonstrated at times inhibition of the virus, however the results did 
· not show consistency throughout the various assays. The siRSV-NSI had no effect on the 
viral proteihs, yet siRSV -NS 1 had inhibition leveis of viral titer of approximately 90%, 
similar to that of siRSV-P2. Zhang et al 9 previously had shown that this siRSV-N'Sl 
sequence greafly attenuated RSV replication in their cellular system, when transfected 
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with a DNA-vector. Our results differed from that of Zhang et al 9 possibly because of 
the difference in transfection methods, where instead of a DNA-vector, a lipid complex 
(i.e. Lipofectamine2000) was used in order to enhance stability. Using this type of carrier 
has been proven effective by Bitko et al at inhibiting RSV replication however it may not 
have been the optimal mode of delivery to the cells for the siRSV-NSl in particular. It 
can also be hypothesized that the inhibition seen at the cellular level may simply be due 
to non-specific off-target effects as the siRSV -NS 1 failed to decrease the protein level but 
did attenuate the viral titer. These off-target effects could have been caused by partial 
complementarity to the RSV mRNA, or by the binding to the target mRNA causing it to 
freqùently induce a moderàte mRNA reduction 303. As sorne of the tested siRNAs showed 
proînising inhibitory effects while others did not, the differences can be influenced by a 
gamut of factors. SiRNA guide (antisense) strands must properly bind to the RISe 
complex in order to search for complementary target mRNA sequences 191. This linkage 
to the RISe complex sometimes may not form, which in consequence, will also be 
difficult to form the 3° structure, thus not allowing for the siRNA to fully carry out its 
silence,pathway to the end. Improper hybridization of the siRNA to target mRNA may 
also lead to variations in efficacy 209. As for the pro-inflammatory cellular response 
observed, generally siRNAs of 21-23 nt can be expected to avoid inducing the interferoh 
response, however even smaller siRNAs have been shown to activate this pathway, 
resulting in global translational blockade and even cell death 304 . 
. Although inhibition of RSV replication was achieved with siRSV-P2, the possibility of 
. enhancing the potency and efficacy with F-ANA modifications was unknown. Therefore, 
three different F -ANA modifications were made of the siRSV -P2 in order to investigate 
their potential enhanced efficacies. Of the three, only siRSV-P2 O/F4 exhibited inhibition 
levels greater than ot similar to the unmodified siRSV -P2 .. With just a modest 
modification to the siRSV -P2 strand at the 3' -end of the antisense strand, siRSV -P2 O/F4 
inhibited the viral P mRNA 30% better than the unmodified siRNA at the lower doses 
while maintaining similar inhibitory effect of approximately 92% at· the highest dose. 
Although this enhanced efficaèy with siRSV-P2 O/F4 at the lower doses was not detected 
to alter levels of hRSV protein nor MIP-la, this F-ANA version did retain equivalent 
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inhibition abilities at both high and low doses· compared to its unmodified % version. 
These results suggested that the dose of potential F-ANA modified siRNA drugs can be 
reduced and still achieve similar levels of inhibition at the mRNA level. Since the 
presence ofF-ANA within DNA or RNA increases the stability of the oligonuc1eotide 10, 
Ferrari 2006 #255 d . Il d h'" h' h . . 
, an potentla y ecreases t e tOXIClty, lt was wort pursumg t e companson 
in vivo. For this, we decided to employa murine model of hRSV infection. 
Despite the shortcomings of using a murine system to study hRSV, inc1uding lack of 
infection of the bronchiolar epithelium, failute to propagate infection from the upper to 
lower airway, and relatively high inoculum required for robust infection and induction of 
pathology and illness 305, we were able to demonstrate efficient intra-nasal inoculation of 
hRSV, with 5x105 PFU per mouse, as determined through the detection ofhRSV mRNA 
and proteins, as well as an increased cellular responses. The advantage of using mice is 
not only its relatively low· cost, but also its comparable response to RSV infection, 
particularly in increased cytokine and chemokine production as well as the cellular 
patterns of lung inflammation that is comparable to that observed in humans. Immune 
responses in our infected BALB/c mice were similar to those previously reported by Jafri 
and colleagues 298, with viral replication peaking, 6 days-post infection and becoming 
undetectable by day 10, also seen by Chavez-Bueno et al 297. Although the hRSV-
infected mi ce did not exhibit any physiological symptoms of pneumonia or loss of 
weight, they did demonstrate higher levels of inflammatory infiltrates compared to those 
mi ce that were .sham infected. The influx of lymphocytes into lungs of hRSV -infected 
mice was visibly more abundant and progressively higher over time than in sham-
infected mice. BAL concentrations of TNF alpha, and mouse MIO were also more 
. ( 
. elevated in hRSV-infected mi ce than in control mice. Taken together, as these results 
bore great resemblance to other BALB/c hRSV models, along with the inhibitory action 
of ribavirin as a control, our in vivo model of hRSV was validated and we were confident 
in commencing treatment with the se1ected siRNAs. 
Base? on their heightened efficacy to inhibit viral repli cation in vitro, the unmodified 
siRNA siRSV-P2 % and its F-ANA modified version siRSV-P2 0/F4, were both 
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selected to be tested for efficacy in our murine hRSV model. Although hRSV infection in 
humans occurs naturally through the nasal route and the virus has an affinity towards 
respiratory epithelial cells, which once propagated, will find itself in the bronchioles, 
justifying bronchoalveolar lavage analysis, however nasal instillation of siRNA may not 
be the optimal method in this hRSV infection murine model. Intratracheal delivery of 
siRNAs was initially tested in the mice (data not shown), howeversome deaths occurred, 
mainly due to their small size and the invasiveness of the procedure.· From those 
observations, intranasal delivery was quickly established as the optimal method for 
administering siRNAs. Several publications have proven that nasal instillation of siRNAs 
was non-invasive and are specifically delivered into the lungs 8, 9, 306. When Massaro et al 
306 instilled micro liter amounts of siRNA mixture into the no se of lightly anesthetized 
mice, results showed elevated targe! mRNA levels specifically in the lungs, whereas 
when administered intraperitoneally, e1evated levels of mRNA were found in the brain 
cortex, cerebellum, and testes, thereby increasing the risk non-specific effects. Bitko 8 
andZhang 9 both aimed at the inhibition of hRSV with siRNAs targeting different viral 
genes through intranasal delivery and both showed promising results using this model. It 
is not somuch an issue of whether the siRNAs were entering the lungs, as opposed to 
staying in the nasal cavity, as the mice were allowed to inhale the siRNA bolus into the 
lungs while lightly anesthetized. In addition, nasal lavage wou Id be difficult to perform 
on such a smaU animal, whereas btonchoalveolar lavage is alni:ady a very standard and 
optimized procedure in mice, thus reinstating that intranasal delivery of siRNA was the 
optimal route for this hRSV murine model. 
Although the control drug treatment of Ribavirin had a greater inhibitory effect in 
reducing the influx of immune cells, inc1uding lymphocytes, neutrophils and eosinophils 
and secretion of the mouse MIG cytokine, it was not as efficient as either the unmodified 
or F-ANA modified siRNAs to inhibit levels of RSV protein or mRNA. SiRNAs are 
designed to specifically inhibit and c1eave target genes, therefore it can be expected that 
siRSV-P2 % and 0/F4 obtained greater levels of knockdown and inhibition at the 
mRNA and prote in levels. Of note, at lower doses, F-ANA modified siRSV-P2· 
successfully reduced viral P mRNA levels 5 times better than the unmodified siRSV -P2, 
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consistent with the results seen in vitro. Although both siRNAs did not inhibit the 
infiltration oflymphocytes in the lungs ofhRSV-infected mice as efficiently as Ribavirin, 
it may be argued that limiting the immune regulating cells is not beneficial for an infected 
individuaL Lymphocytes play a key role in the identification and destruction of foreign 
particles. Although infection by hRSV.ininfants and young children may cause illnesses 
such as bronchiolitis whiCh is an inflammation of the small airwâys of the lungs, there 
. . 
. exists the possibility that interfering with the infiltration of immune cells into target 
infected areas may result in more harm than allowing for the presence of inflammatory 
immune cells. When presented with the virus, lymphocytes are attracted to the site of 
infection, i.e. the lungs, and their presence is required for the termination of viral 
, 
replication, recovery from primary infection and protection from re-infection 125. Studies 
of RSV infection in mouse models have demonstrated that i~ previously naïve animaIs, 
cytotoxic T lymphocytes and antibodies both play a role in eradicating RSV from the 
respiratory tract 307 125, in that T lymphocytes are an important determinant of illness and 
that antibodies are postulated to be an illness-sparing mechanism for the protection of the 
mice against hRSV infection. Therefore the allowance of lymphocyte infiltration may be 
in fact an advantage since it aiso correlated with the presence of illness. Not aU immune 
ceU influx may play a direct role in controlling the infection as the rise in neutrophils on 
the clay following infection in both sham-infected and hRSV-infected mice demonstrates 
that the simple action of administering a small volume of liquid into the nasal cavity and 
lungs can stimulate an immediate response during the acute phase of infection. 
Though daily treatment with ribavirin appeared to inhibitoverall hRSV infectioIl, a single 
small dose of siRNAs administered to mice once was effective enough at inhibiting viral 
replication by almost half. Inhibition levels of hRSV proteins achieved by both ribavirin 
and F-ANA modified siRSV-P2 at the highest dose are comparable, thus similar potency. 
Even more remarkable w,as the knockdown of target hRSV P mRNA in lung of hRSV-
infected mice treated with the low 25 Ilg dose of siRSV-P2 O/F4. The effect was 61 % 
greater than that observed with ribavirin. These results have the potential to be clinically 
important, as a tolerable therapeutic dose of siRNA for nasal installation could be 
envisioned for humans, with possibly less repeated dosing. 
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From the results presented in this study, it is apparent that notonly did unmodified 
siRSV-P2 inhibit 'viral replication in vitro, but that a mode st substitution of two riboses 
with F-ANA placed at the 3' end of the antisense strand of siRSV-P2 (siRSV-P2 O/F4) 
improved its efficacy by 30% at the lowest dose. Animal studies demonstrated that 
unmodified siRSV.:.P2 was effective in vivo at inhibiting viral replication in a dose 
dependent manner when simply administered intra-nasally. Although siRSV-P2 O/F4 
obtained greater inhibitIon at the mRNA level when instilled at the lower dose, overall 
the F-ANA modifications to the siRNA maintained a similar levels of efficacy as the 
unmodified siRNA at the 50 !Ag dose for all readouts. Further studies may be performed 
to assess the potential of other placement of F-ANA along the siRNA duplexes for 
improved efficacy both in vitro and in vivo. Although only one chemistry of F-ANA was 
tested in our RSV mouse model, in other in vitro models an assortment of F-ANA 
modifications to siRNAs have been screened by Dowler et al 10 and we selected our F-
ANA modification based on the success of this modification in their system. There is no 
guarantee that a modification that is effective in one system will be the best inanother 
system. More F-ANA versions should be tested for more desirable levels of inhibition of 
hRSV infection in vivo. Furthermore, the berieficial effect ofF-ANA over native siRNAs 
is often detectable at low doses or over longer periods of time because of increased 
stabilit)r, arguing for the need offurther studies to be done. 
Various dosing regimens and delivery mechanisms have been examined by others in 
order to improve the activity and stability of the siRNAs. In our study, various doses of 
up to 50 !Ag per mouse were examined however siRNAs were administered only at a 
single time point on the saille day as hRSV inoculation. Different timing strategies may 
be employed, such as several ho urs and also days post-infection or ev en re-dosing post-
-
infection, so as to prolong the presence of siRNAs so as to inhibit hRSV replication. 
Unmodified and F-ANA modified siRNAs may also be investigated as a method of 
prophylaxis if treatment were to occur prior to hRSV infection. The frequency of dosing 
may be reduced if the stability of the siRNAs were to be strengthened. As discussed in 
the introduction, the stability of the siRNAs can be greatly enhanced if a delivery 
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mechanism were to be employed, such as cholesterol-conjugation, aptamer-conjugation 
and liposome-formulations. Although our in vitro screening of siRNAs were conducted 
with a Lipofectamine 2000 as a lipid carrier, investigations in mice were executed with 
naked siRNAs instilled directly into the nose of the animaIs. Bitko et al. estimated that 
the naked siRNA was 70-80% as effective as the siRNA complexed 'with transfection 
reagent. This finding along with our results using naked siRNAs is of particular 
importance âs transfedion reagents themselves may have adverse effects. Our results 
clearly demonstrate that siRNAs delivered unguarded may offer substantial protection 
against hRSV. 
In conclusion, our data showed that naked unmodified and F-ANA modified si RNA 
reduced the infection and repli cation by hRSV in A549 ceUs and· in mice wh en 
administered intra-nasaUy. Treatment with siRSV-P2 0/F4 retains the degree of efficacy 
observed with siRSV -P2 % in vivo, however chemical modification of this siRNA with 
F-ANA did not lead to dramatic improvements of its in vivo efficacy, except for a trend 
, for more efficacy at lower doses. Daily therapy with ribavirin obtained similar inhibition 
of RSV infection (as assessed by knockdown at the mRNA level) as F-ANA modified 
siRSV -P2, however the cumulative dose of ribavirin to achieve this level of efficacy was 
75-fold greater than the dose of siRNA. These findings are encouraging and indicate the 
need for more research especially focusing on areas such as prolonging the siRNA half-
life, enhancing their stability, incrèasing their affinity with RNA and bio-distribution 
without compromising biological activity, in order toconvert these siRNAs into 
optimized prophylactic and/or therapeutic agents against hRSV infection in humans. 
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